

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051936 A1

(51) International Patent Classification⁷: C07D 307/68,
A61K 31/341, A61P 35/00

ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2004/035527

(22) International Filing Date:
16 November 2004 (16.11.2004)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/051936 A1

(54) Title: PHENYL-FURAN COMPOUNDS AS VITAMIN D RECEPTOR MODULATORS

(57) Abstract: The present invention relates to novel, non-secosteroidal, phenyl-furan compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1 α ,25dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

PHENYL-FURAN COMPOUNDS AS VITAMIN D RECEPTOR MODULATORS

BACKGROUND OF THE INVENTION

5 Vitamin D₃ Receptor (VDR) is a ligand dependent transcription factor that belongs to the superfamily of nuclear hormone receptors. The VDR protein is 427 amino acids, with a molecular weight of ~50 kDa. The VDR ligand, 1 α ,25-dihydroxyvitamin D₃ (the hormonally active form of Vitamin D) has its action mediated by its interaction with the nuclear receptor known as Vitamin D receptor ("VDR"). The VDR ligand, 1 α ,25-
10 dihydroxyvitamin D₃ (1 α ,25(OH)₂D₃) acts upon a wide variety of tissues and cells both related to and unrelated to calcium and phosphate homeostasis.

The activity of 1 α ,25-dihydroxyvitamin D₃ (1 α ,25(OH)₂D₃) in various systems suggests wide clinical applications. However, use of conventional VDR ligands is hampered by their associated toxicity, namely hypercalcemia (elevated serum calcium).

15 Currently, 1 α ,25(OH)₂D₃, marketed as Rocaltrol® pharmaceutical agent (product of Hoffmann-La Roche), is administered to kidney failure patients undergoing chronic kidney dialysis to treat hypocalcemia and the resultant metabolic bone disease. Other therapeutic agents, such as Calcipotriol® (synthetic analog of 1 α ,25(OH)₂D₃) show increased separation of binding affinity on VDR from hypercalcemic activity.

20 Recently, chemical modifications of 1 α ,25(OH)₂D₃ have yielded analogs with attenuated calcium mobilization effects (R. Bouillon et. al., Endocrine Rev. 1995, 16, 200-257). One such analog, Dovonex ® pharmaceutical agent (product of Bristol-Meyers Squibb Co.), is currently used in Europe and the United States as a topical treatment for mild to moderate psoriasis (K. Kragballe et. al., Br. J. Dermatol. 1988, 119, 223-230).

25 Other vitamin D₃ mimics have been described in the publication, Vitamin D Analogs: Mechanism of Action of Therapeutic Applications, by Nagpal, S.; Lu, J.; Boehm, M. F., Curr. Med. Chem. 2001, 8, 1661-1679.

30 Although some degree of separation between the beneficial action and calcium raising (calcemic) effects has been achieved with these VDR ligands, to date the separation has been insufficient to allow for oral administration to treat conditions such as osteoporosis, cancers, leukemias, and severe psoriasis.

-2-

One example of a major class of disorder that could benefit from VDR mediated biological efficacy in the absence of hypercalcemia is osteoporosis. Osteoporosis is a systemic disorder characterized by decreased bone mass and microarchitectural deterioration of bone tissue leading to bone fragility and increased susceptibility to fractures of the hip, spine, and wrist (World Health Organization WHO 1994).
5 Osteoporosis affects an estimated 75 million people in the United States, Europe, and Japan.

Within the past few years, several antiresorptive therapies have been introduced. These include bisphosphonates, hormone replacement therapy (HRT), a selective estrogen 10 receptor modulator (SERM), and calcitonins. These treatments reduce bone resorption, bone formation, and increase bone density. However, none of these treatments increase true bone volume nor can they restore lost bone architecture.


Synthetic vitamin D receptor (VDR) ligands with reduced calcemic potential have been synthesized. For example, a class of bis-phenyl compounds stated to mimic 1 α , 25-dihydroxyvitamin D₃ is described in US Patent No. 6,218,430 and the article; "Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1 α , 25-Dihydroxyvitamin D₃" by Marcus F. Boehm, et. al., Chemistry & Biology 1999, Vol 6, No. 5, pgs. 265-275.

There remains a need for improved treatments using alternative or improved 20 pharmaceutical agents that mimic 1 α , 25-dihydroxyvitamin D₃ to stimulate bone formation, restore bone quality, and treat other diseases without the attendant disadvantage of hypercalcemia.

SUMMARY OF THE INVENTION


25

Novel compounds having a nucleus of formula "(A)" have been found effective as Vitamin D Receptor (VDR) modulators:



-3-

Compounds of the present invention with VDR modulating activities are represented by formula (I)



- 5 wherein the variables R, R', R_P, R'_P, L₁, L₂, L₃, Z_P, R_F, L_F, and Z_F, and are as hereinafter defined. The inventors have discovered that compounds described herein display the desirable cell differentiation and antiproliferative effects of 1,25(OH)₂D₃ with reduced calcium mobilization (calcemic) effects.

In another aspect, the present invention is directed towards pharmaceutical compositions containing pharmaceutically effective amounts of compounds of formulae I or a pharmaceutically acceptable salt or prodrug thereof, either singly or in combination, together with pharmaceutically acceptable carriers and/or auxiliary agents.

Another aspect of the invention are novel chemical intermediates suitable for preparing the compounds of Formula I.

15 Another aspect of the invention is to use the compounds of the invention to treat or prevent disease states responsive to Vitamin D receptor ligands.

Another aspect of the invention is the prevention and treatment of Acne, Actinic keratosis, Alopecia, Alzheimer's disease, Benign prostatic hyperplasia, Bladder cancer, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer,

20 Chemoprevention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia, Type II diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum secretion, Osteomalacia, Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration, Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid arthritis, Scleroderma, Skin cancer, 25 Systemic lupus erythematosus, Skin cell damage from Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles; by administering to a mammal in need thereof a

-4-

pharmaceutically effective amount of a compound of Formula I.

Another aspect of the invention is the use of the compounds of Formula I for treating or preventing disease states mediated by the Vitamin D receptor.

5

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions:

The word "adhesion" refers to the abnormal union of surfaces normally separate by the formulation of new fibrous tissue resulting from an inflammatory process.

10 The word "abscess" is a complication often associated with surgery, trauma, or diseases that predispose the host to abscess formation from encapsulated bacteria lymphocytes, macrophages, and etc.

15 The term "alkenyl" refers to aliphatic groups wherein the point of attachment is a carbon-carbon double bond, for example vinyl, 1-propenyl, and 1-cyclohexenyl. Alkenyl groups may be straight-chain, branched-chain, cyclic, or combinations thereof, and may be optionally substituted. Suitable alkenyl groups have from 2 to about 20 carbon atoms.

The term "alkoxy" refers to -OR wherein R is an aliphatic or aromatic group which may be optionally substituted. Methoxy, ethoxy, propoxy, butoxy, and phenoxy are examples of alkoxy groups.

20 The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain, cyclic and any combinations thereof. Alkyl groups may further be divided into "primary", "secondary", and "tertiary" alkyl groups. In primary alkyl groups, the carbon atom of attachment is substituted with zero (methyl) or one organic radical. In secondary alkyl groups, the carbon atom of attachment is substituted with two organic radicals. In tertiary alkyl groups, the carbon atom of attachment is substituted with three organic radicals.

25 The term "cycloalkyl" includes organic radicals such as cyclopropanyl, cyclobutanyl, and cyclopentyl.

30 The term, "cycloalkenyl" includes organic radicals such as cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl.


The term, "C₁-C₅ fluoroalkyl" refers to an alkyl group containing fluorine and includes organic radicals such as -CF₃, -CHF₂, -CH₂F, -CF₂CF₃, -CHFCF₃, -CH₂CF₃,

-5-

-CH₂CHF₂, and -CH₂CH₂F, with -CF₃ being preferred.

The term, "Active Ingredient" refers to a compound of the invention represented by any of (i) formulae I, II, III, IV, (ii) the product of any example set out herein, or (iii) a compound identified in any row of Tables 1, 2, 3, or 4; or a salt or prodrug derivative of
5 the preceding compound.

The term "carboxamide" refers to a group represented by the formulae:



where R4 and R5 are independently hydrogen, C₁-C₄ alkyl, -O-C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ haloalkyl, -NH(C₁-C₄ alkyl), or cyclopropyl, with the proviso that
10 only one of R4 or R5 may be hydrogen.

The abbreviation, "Me" means methyl.

The abbreviation, "Et" means ethyl.

The abbreviation, "iPr" means 1-methylethyl.

The abbreviation, "tBu" means 1,1-dimethylethyl.

15 The symbol "-(CH₂)₂- is equivalent to -CH₂-CH₂-.

The univalent symbol "-O" in any structural formula is a hydroxyl group (-OH).

The term, "C₁-₃ alkyl" refers to an alkyl group selected from methyl, ethyl, n-propyl, and isopropyl.

20 The term, "branched C₃-C₅ alkyl" is an alkyl group selected from 1-methylethyl; 1-methylpropyl; 2-methylpropyl; 1,1-dimethylethyl; 1,1-dimethylpropyl; 1,2-dimethylpropyl; or 2,2-dimethylpropyl. Preferred branched C₃-C₅ alkyl groups are 2-methylpropyl and 1,1-dimethylethyl, with the 1,1-dimethylethyl group being most preferred.

25 The term "alkenyl" refers to aliphatic groups wherein the point of attachment is a carbon-carbon double bond, for example vinyl, 1-propenyl, and 1-cyclohexenyl. Alkenyl groups may be straight-chain, branched-chain, cyclic, or combinations thereof, and may be optionally substituted. Suitable alkenyl groups have from 2 to about 20 carbon atoms.

The term "C₁-C₅ alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain, and cyclic groups and any combinations thereof. Alkyl groups

-6-

may further be divided into "primary", "secondary", and "tertiary" alkyl groups. In primary alkyl groups, the carbon atom of attachment is substituted with zero (methyl) or one organic radical. In secondary alkyl groups, the carbon atom of attachment is substituted with two organic radicals. In tertiary alkyl groups, the carbon atom of attachment is substituted with three organic radicals. Examples of C₁-C₅ alkyl groups are methyl, ethyl, n-propyl, from 1-methylethyl; n-butyl, 1-methylpropyl; 2-methylpropyl; 1,1-dimethylethyl; n-amyl, 1,1-dimethylpropyl; 1,2-dimethylpropyl; and 2,2-dimethylpropyl.

5 The term "cycloalkyl" includes organic radicals such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

10 The term, "cycloalkenyl" includes organic radicals such as cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl.

The term, "C₁-C₅ fluoroalkyl" is an alkyl group containing fluorine and includes organic radicals such as -CF₃, -CHF₂, -CH₂F, -CF₂CF₃, -CHFCF₃, -CH₂CF₃, -CH₂CHF₂, and -CH₂CH₂F, with -CF₃ being preferred.

15 The abbreviation, "Me" means methyl.

The abbreviation, "Et" means ethyl.

The abbreviation, "iPr" means 1-methylethyl.

The abbreviation, "tBu" means 1,1-dimethylethyl.

The term, "terminal hydroxyalkyl" refers to a group selected from

20 3-methyl-3-hydroxypentyl,
3-methyl-3-hydroxypentenyl,
3-methyl-3-hydroxypentynyl,
3-ethyl-3-hydroxypentyl,
3-ethyl-3-hydroxypentenyl,

25 3-ethyl-3-hydroxypentynyl,
3-ethyl-3-hydroxy-4-methylpentyl,
3-ethyl-3-hydroxy-4-methylpentenyl,
3-ethyl-3-hydroxy-4-methylpentynyl,
3-propyl-3-hydroxypentyl,


30 3-propyl-3-hydroxypentenyl,
3-propyl-3-hydroxypentynyl,
1-hydroxy-2-methyl-1-(methylethyl)propyl,

-7-


1-hydroxy-2,2-dimethylpropyl,
 1-hydroxy-1,2,2-trimethylpropyl,
 1-hydroxycycloalkenyl; and
 1-hydroxycycloalkyl.

5


The term, "3-methyl-3-hydroxypentyl" refers to the radical having the structural formula:




10 The term, "3-methyl-3-hydroxypentenyl" refers to the radical having the structural formula (both cis and trans isomers):




15 The term, "3-methyl-3-hydroxypentynyl" refers to the radical having the structural formula:



The term, "3-ethyl-3-hydroxypentyl" refers to the radical having the structural formula:




The term, "3-ethyl-3-hydroxypentenyl" refers to the radical having the structural formula (both cis and trans isomers):




20

-8-


The term, "3-ethyl-3-hydroxypentynyl" refers to the radical having the structural formula:




5 The term, "3-propyl-3-hydroxypentyl" refers to the radical having the structural formula:




10 The term, "3-propyl-3-hydroxypentenyl" refers to the radical having the structural formula (both cis and trans isomers):



15 The term, "3-ethyl-3-hydroxypentynyl" refers to the radical having the structural formula:




15 The term, "3-ethyl-3-hydroxy-4-methylpentyl" refers to the radical having the structural formula:




-9-


The term, "3-ethyl-3-hydroxy-4-methylpentenyl" refers to the radical having the structural formula (both cis and trans isomers):




5 The term, "3-ethyl-3-hydroxy-4-methylpentynyl" refers to the radical having the structural formula:




The term, "1-hydroxy-2-methyl-1-(methylethyl)propyl" refers to the radical having the structural formula:



10 The term, "1-hydroxy-2,2-dimethylpropyl" refers to the radical having the structural formula:



The term, "1-hydroxy-1,2,2-trimethylpropyl" refers to the radical having the structural formula:




15

The term, "1-hydroxycycloalkenyl" refers to a radical selected from 1-hydroxycyclopentenyl, 1-hydroxycyclohexenyl, 1-hydroxycycloheptenyl, or 1-

-10-


hydroxycyclooctenyl.

The term "hydroxycycloalkyl" refers to a radical having the general structural formula:



- 5 where w is an integer from 1 to 6 and the hydroxyl radical is substituted on any ring carbon atom.

The term "1-hydroxycycloalkyl" refers to a radical having the general structural formula:



- 10 Examples of 1-hydroxycycloalkyl radicals are
1-hydroxycyclopropyl, 1-hydroxycyclobutyl, 1-hydroxycyclopentyl,
1-hydroxycyclohexyl, 1-hydroxycycloheptyl, and 1-hydroxycyclooctyl.
The abbreviation, "Me" means methyl.
The abbreviation, "Et" means ethyl.
15 The abbreviation, "iPr" means 1-methylethyl.
The abbreviation, "nPr" means n-propyl.
The abbreviation, "3Me3OH-Pentyl" means 3-methyl-3-hydroxypentyl.
The abbreviation, "3Me3OH-Pentenyl" means 3-methyl-3-hydroxypentenyl
The abbreviation, "3Me3OH-Pentynyl" means 3-methyl-3-hydroxypentynyl
20 The abbreviation, "3Et3OH-Pentyl" means 3-ethyl-3-hydroxypentyl.
The abbreviation, "3Et3OH-Pentenyl" means 3-ethyl-3-hydroxypentenyl
The abbreviation, "3Et3OH-Pentynyl" means 3-ethyl-3-hydroxypentynyl
The abbreviation, "3Pr3OH-Pentyl" means 3-propyl-3-hydroxypentyl.
The abbreviation, "3Pr3OH-Pentenyl" means 3-propyl-3-hydroxypentenyl.
25 The abbreviation, "3Pr3OH-Pentynyl" means 3-propyl-3-hydroxypentynyl.
The abbreviation, "3Et3OH4Me-Pentyl" means 3-ethyl-3-hydroxy-4-methylpentyl.

-11-

The abbreviation, "3Et3OH4Me-Pentenyl" means 3-ethyl-3-hydroxy-4-methylpentenyl,

The abbreviation, "3Et3OH4Me-Pentynyl" means 3-ethyl-3-hydroxy-4-methylpentynyl.

5 The abbreviation, "1OH2Me1MeEt-Propyl" means 1-hydroxy-2-methyl-1-(methylethyl)propyl.

The term "C₁-C₅ alkyl" is an alkyl substituent selected from the group consisting of : methyl; ethyl; propyl; 1-methylethyl; 1-methylpropyl; 2-methylpropyl; 1,1-dimethylethyl; 1,1-dimethylpropyl; 1,2-dimethylpropyl; and 2,2-dimethylpropyl. The 10 preferred groups are 2-methylpropyl and 1,1-dimethylethyl, with the 1,1-dimethylethyl group being most preferred.

The dotted line symbol crossing a solid line representing a bond



means that the bond so marked is point of attachment.

15 The term, "mammal" includes humans.


The term "halo" refer to fluorine, chlorine, bromine, and iodine.

The term "pharmaceutically acceptable salt" refers to conventional non-toxic anionic or cationic salts conventionally used in therapeutic compounds, for example, sodium and potassium.

20

Compounds of the Invention:

The compounds of the invention are Vitamin D Receptor Modulators represented by formula I or a pharmaceutically acceptable salt or prodrug derivative thereof:



25

-12-

wherein;





R and R' are independently C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, or together R and R' form a substituted or unsubstituted, saturated or unsaturated carbocyclic ring having from 3 to 8 carbon atoms;

5 R_P, R_{P'}, and R_F are independently selected from the group consisting of hydrogen, halo, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ fluoroalkyl, -O-C₁-C₄ alkyl, -S-C₁-C₄ alkyl, -O-C₁-C₄ fluoroalkyl, -CN, -NO₂, acetyl, -S-C₁-C₄ fluoroalkyl, C₂-C₄ alkenyl, C₃-C₄ cycloalkyl, and C₃-C₄ cycloalkenyl;

(L₁), (L₂), (L₃), and (L_F) are divalent linking groups independently selected from
10 the group consisting of

a bond,


oxygen



where each R40 is independently hydrogen, C₁-C₅ alkyl or C₁-C₅ fluoroalkyl;

where X1 is O, CH₂ or [H, OH];

15 Z_F is



-13-

where R4 and R5 are independently hydrogen, C₁-C₄ alkyl, -O-C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ haloalkyl, -NH(C₁-C₄ alkyl), or cyclopropyl, with the proviso that only one of R4 or R5 may be hydrogen.

Z_p is

5	methyl, ethyl, n-propyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl,
10	1-hydroxy-2,2-dimethylpropyl, 1-hydroxy-1,2,2-trimethylpropyl, 2-hydroxy-2-methylbutoxy 2-hydroxy-2-ethylbutoxy 2-hydroxy-2-ethyl-3-methylbutoxy
15	2-hydroxy-2-methyl-3-methylbutoxy 2-hydroxy-1,3,3-trimethylbutoxy 2-hydroxy-1-ethyl-3,3-dimethylbutoxy 2-hydroxy-1,2-diethylbutoxy 2-hydroxy-2-ethyl-1-methylbutoxy
20	3-methyl-3-hydroxypentyl, 3-methyl-3-hydroxypentenyl, 3-methyl-3-hydroxypentynyl, 3-ethyl-3-hydroxypentyl, 3-ethyl-3-hydroxypentenyl,
25	3-ethyl-3-hydroxypentynyl, 3-ethyl-3-hydroxy-4-methylpentyl, 3-ethyl-3-hydroxy-4-methylpentenyl,
30	

-14-

- 3-ethyl-3-hydroxy-4-methylpentynyl,
3-propyl-3-hydroxypentyl,
3-propyl-3-hydroxypentenyl,
3-propyl-3-hydroxypentynyl,
5 1-hydroxy-2-methyl-1-(methylethyl)propyl
1-hydroxycyclopentenyl,
1-hydroxycyclohexenyl,
1-hydroxycycloheptenyl,
1-hydroxycyclooctenyl,
10 1-hydroxycyclopropyl,
1-hydroxycyclobutyl,
1-hydroxycyclopentyl,
1-hydroxycyclohexyl,
1-hydroxycycloheptyl, or
15 1-hydroxycyclooctyl.

Preferred compounds of the invention are when Z_p is 1,1-dimethylethyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-hydroxy-2,2-dimethylpropyl, and 1-hydroxy-1,2,2-trimethylpropyl; provided that (L_1), (L_2), (L_3) are all bonds (viz.,
20 Z_p is attached directly to the phenyl ring of the nucleus).

Preferred compound have Z_F selected from:

- C(O)NHMe,
-C(O)NHEt,
-C(O)NH(iPr),
25 -C(O)NH(tBu),
-C(O)NH(CF₃),
-C(O)N(Me)₂,
-C(O)NMeEt,
-C(O)NMe(iPr),
30 -C(O)NMe(tBu),
-C(O)NMe(CF₃),
-C(O)N(Me)F,

-15-

- C(O)N(Et)F
- C(O)N(iPr)F,
- C(O)N(tBu)F,
- C(O)N(Et)₂,
- 5 -C(O)NET(iPr), or
- C(O)NET(tBu).









Other preferred compounds have Z_F selected from:

- C(O)NHMe,
- 10 -C(O)NHEt,
- C(O)NH(iPr),
- C(O)NH(tBu),
- C(O)N(Me)₂,
- C(O)NMeEt,
- 15 -C(O)NMe(iPr),
- C(O)NMe(tBu),
- C(O)N(Et)₂,
- C(O)NET(iPr), or
- C(O)NET(tBu).

20

A preferred carboxamide group Z_F is

-16-




or

-17-

PREFERRED COMPOUNDS OF THE INVENTION ARE REPRESENTED BY FORMULAE


A TO K AS FOLLOWS:

A)




5

B)




C)




10

D)




-18-

E)




F)




5


G)



H)




I)



10


-19-

J)



, and

K)



5

EXAMPLES

General Experimental Conditions:

The starting material/intermediate is the compound from the immediate preceding
10 experimental unless otherwise indicated.

All reactions are performed under nitrogen/argon atmosphere, in a stirred reaction vessel, and at room temperature unless indicated otherwise.

Concentration is performed from RT to about 70°C under vacuum (0.05 to 1 mm Hg).

15 Unless otherwise indicated, the organic layer is MgSO₄/Na₂SO₄ dried is defined as stirring the solution with a dessicant for 5-15 m and filtering off the dessicant to give an anhydrous filtrate.

For analogous multi-step reaction procedures, the yield is given either for the ultimate step or overall multi-steps as indicated.

20 Solutions are “concentrated” at a range of 25-75 °C with reduced pressure.
in-vacuo – 25-75 °C; 0.05 to 1 mm

Unless otherwise indicated, “the residue is chromatographed” is defined as silica gel chromatography of residue with moderate nitrogen pressure (flash chromatography) or

-20-

a medium pressure chromatography systems using a silica gel to crude product ratio of ~10-100.

Thin layer chromatography is performed with silica gel plates with UV and/or appropriate staining solution.

5 NMR spectra are obtained with either 300 or 400 mHz spectrometer.

NMR – denotes NMR spectrum is consistent with assigned structure.

HRMS – high resolution mass spectrum

ES-MS – electrospray mass spectrum

Abbreviations:

10 Aq - aqueous

d – day

eq - equivalent

h – hour

m – minute

15 satd – saturated

disp – dispersion

quant – quantitative

rt for retention time (both small caps to minimize confusion with RT)

RT – room temperature

20

Chemical Definitions:

BnBr – benzyl bromide

CH₂Cl₂-dichloromethane

CH₃CN – acetonitrile

25 DIBALH - Diisobutyl Aluminum Hydride

DMAP - 4-(dimethylamino)pyridine

DMF – N,N-dimethylformamide

DMSO – dimethylsulfoxide

DPPB – 1,4-bis(diphenylphosphino)butane

30 DPPF – dichloro[1,1'-bis(diphenylphosphino)ferrocene

EDCI – 3-Ethyl-1-[3-(dimethylamino)propyl]carbodiimide hydrochloride

Et₃N – triethylamine

-21-

- EtMgBr- ethyl magnesium bromide
EtOAc – ethyl acetate
EtOH – ethanol
H2NCH2CO2Me – methyl glycinate
5 Hept – heptane
Hex - hexanes
HN(OMe)Me – N-methyl-O-methyl hydroxylamine
HNMe2 – dimethyl amine
HATU – O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
10 hexafluorophosphate
HOAT – 7-aza-1-hydroxybenzotriazole
HOBT – 1-hydroxybenzotriazole
K2CO3 – potassium carbonate
KOH – potassium hydroxide
15 LAH – lithium aluminum hydride
LiHMDS – lithium hexamethyldisilazide
mCPBA – meta-chloroperbenzoic acid
MeI – methyl iodide
MeOH – methanol
20 NaBH4 – sodium borohydride
MgSO4- magnesium sulfate
NaH – sodium hydride
NaHCO3-sodium bicarbonate
NaI – sodium iodide
25 Na2SO4- sodium sulfate
NH4Cl- ammonium chloride
NMO – 4-methylmorpholine N-oxide
NMP - N-methylpyrrolidin-2-one
Na-S-R3 – sodium alkylmercaptide
30 PBr3 – phosphorus tribromide
Pd(DPPF) - palladium dichloro[1,1'-bis(diphenylphosphino)ferrocene]
Pd(OAc)2 – palladium (II) acetate

-22-

- Pd(TPP)4 – palladium tetrakis(triphenylphosphine)
Pd-C – palladium on carbon
(PhO)2P(O)N3 – diphenyl phosphorus azide
pTSA – para-toluenesulfonic acid
5 Pyr – pyridine
Red-Al – sodium bis(2-methoxyethoxy)aluminum hydride
R2MgBr – alkyl magnesium bromide
R3MgBr – alkyl magnesium bromide
R5MgBr – alkyl magnesium bromide
10 R2S(O)2NH2 – alkylsulfonamide
TBAF- tetrabutylammonium fluoride
TBSCl- *tert*-butyldimethylsilyl chloride
tBuC(O)CH2Br – 1-bromopinacolone
Tf2O – triflic anhydride
15 TFA – trifluoroacetic acid
THF – tetrahydrofuran
TPAP – tetrapropylammonium perruthenate
Zn(OTf)2 – zinc trifluoromethane sulfonate.

Compounds of the Invention – Salts, Stereoisomers, & Prodrugs:

20 Salts of the compounds represented by formulae I are an additional aspect of the invention. The skilled artisan will also appreciate that the family of compounds of formulae I include acidic and basic members and that the present invention includes pharmaceutically acceptable salts thereof.

In those instances where the compounds of the invention possess acidic or basic 25 functional groups various salts may be formed which are more water soluble and physiologically suitable than the parent compound. Representative pharmaceutically acceptable salts, include but are not limited to, the alkali and alkaline earth salts such as lithium, sodium, potassium, ammonium, calcium, magnesium, aluminum, zinc, and the like. Sodium and potassium salts are particularly preferred. Salts are conveniently 30 prepared from the free acid by treating the acid in solution with a base or by exposing the acid to an ion exchange resin. For example, a carboxylic acid substituent on the compound of Formula I may be selected as -CO₂H and salts may be formed by reaction

with appropriate bases (e.g., NaOH, KOH) to yield the corresponding sodium and potassium salt.

Included within the definition of pharmaceutically acceptable salts are the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, *et al.*, "Pharmaceutical Salts," *J. Phar. Sci.*, 66: 1-19 (1977)). Moreover, the basic group(s) of the compound of the invention may be reacted with suitable organic or inorganic acids to form salts such as acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, choline, clavulanate, citrate, chloride, chloroprocaine, choline, diethanolamine, dihydrochloride, diphosphate, edetate, edisylate, estolate, esylate, ethylenediamine, fluoride, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, bromide, chloride, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, malseate, mandelate, meglumine, mesylate, mesviate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, palmitate, pamoate, pantothenate, phosphate, polygalacturonate, procane, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclolate, tosylate, trifluoroacetate, trifluoromethane sulfonate, and valerate.

Certain compounds of the invention may possess one or more chiral centers and may thus exist in optically active forms. Likewise, when the compounds contain an alkenyl or alkenylene group there exists the possibility of cis- and trans- isomeric forms of the compounds. The R- and S- isomers and mixtures thereof, including racemic mixtures as well as mixtures of cis- and trans- isomers, are contemplated by this invention. Additional asymmetric carbon atoms can be present in a substituent group such as an alkyl group. All such isomers as well as the mixtures thereof are intended to be included in the invention. If a particular stereoisomer is desired, it can be prepared by methods well known in the art by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively by methods which lead to mixtures of the stereoisomers and subsequent resolution by known

-24-

methods. For example, a chiral column may be used such as those sold by Daicel Chemical Industries identified by the trademarks:

CHIRALPAK AD, CHIRALPAK AS, CHIRALPAK OD, CHIRALPAK OJ,

CHIRALPAK OA, CHIRALPAK OB, CHIRALPAK OC, CHIRALPAK OF,

5 CHIRALPAK OG, CHIRALPAK OK, and

CHIRALPAK CA-1.

By another conventional method, a racemic mixture may be reacted with a single enantiomer of some other compound. This changes the racemic form into a mixture of diastereomers. These diastereomers, because they have different melting points, different
10 boiling points, and different solubilities can be separated by conventional means, such as crystallization.

The present invention is also embodied in mixtures of compounds of formulae I.

Prodrugs are derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become by solvolysis or under physiological
15 conditions the compounds of the invention which are pharmaceutically active in vivo. Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives
20 well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine.

Pharmaceutical Formulations containing the Novel Compounds of the Invention:

25 Pharmaceutical formulations of the invention are prepared by combining (e.g., mixing) a therapeutically effective amount of the compound of the invention (compounds of Formula I) together with a pharmaceutically acceptable carrier or diluent. The present pharmaceutical formulations are prepared by known procedures using well-known and readily available ingredients.

30 In making the compositions of the present invention, the compounds of Formula I will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container.

-25-

When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), or ointment, containing, for example, up to 10% by weight of the
5 compound. The compounds of the present invention are preferably formulated prior to administration.

The compounds of the invention may also be delivered by suitable formulations contained in a transderm patch. Alternatively, the compounds of the invention may be delivered to a patient by sublingual administration.

10 For the pharmaceutical formulations any suitable carrier known in the art can be used. In such a formulation, the carrier may be a solid, liquid, or mixture of a solid and a liquid. Solid form formulations include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, binders, tablet disintegrating agents and encapsulating
15 material.

Tablets for oral administration may contain suitable excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, together with disintegrating agents, such as maize, starch, or alginic acid, and/or binding agents, for example, gelatin or acacia, and lubricating agents such as magnesium stearate, stearic acid, or
20 talc.

In powders the carrier is a finely divided solid which is in admixture with the finely divided Active ingredient. In tablets the compound of Formula I is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about 1 to
25 about 99 weight percent of the compound which is the novel compound of this invention. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes, and cocoa butter.

Sterile liquid form formulations include suspensions, emulsions, syrups and
30 elixirs.

The Active Ingredient may be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both. The

-26-

compounds can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol. Other compositions can be made by dispersing the finely divided compounds of the invention in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.

5

Methods of Using the Compounds of the Invention:

Many disease states are benefited by treatment with the compounds of Formula I include, but are not limited to:

- 10 disease states characterized by abnormal calcium regulation
- disease states characterized by abnormal cell proliferation
- disease states characterized by abnormal cell differentiation
- disease states characterized by abnormal immune response
- disease states characterized by abnormal dermatological conditions
- disease states characterized by neurodegenerative condition
- 15 disease states characterized by inflammation
- disease states characterized by vitamin D sensitivity
- disease states characterized by hyperproliferative disorders.

Specific disease states benefited by treatment of the compounds of Formula I and II
20 include, but are not limited to:

- Acne
- Actinic keratosis
- Alopecia
- Alzheimer's disease
- 25 Benign prostatic hyperplasia
- Bladder cancer
- Bone maintenance in zero gravity
- Bone fracture healing
- Breast cancer
- 30 Chemoprevention of Cancer
- Crohn's disease
- Colon cancer

-27-

- 5 Type I diabetes
- Host-graft rejection
- Hypercalcemia
- Type II diabetes
- Leukemia
- Multiple sclerosis
- Myelodysplastic syndrome
- Insufficient sebum secretion
- Osteomalacia
- 10 Osteoporosis
- Insufficient dermal firmness
- Insufficient dermal hydration
- Psoriatic arthritis
- Prostate cancer
- 15 Psoriasis
- Renal osteodystrophy
- Rheumatoid arthritis
- Scleroderma
- Skin cancer
- 20 Systemic lupus erythematosus
- Skin cell damage from Mustard vesicants
- Ulcerative colitis
- Vitiligo
- Wrinkles
- 25 Particularly preferred is the treatment of psoriasis and osteoporosis by administration to a mammal (including a human) of a therapeutically effective amount of compounds of Formulae I. By "pharmaceutically effective amount" it is meant that quantity of pharmaceutical agent corresponding to formulae I which prevents, removes or reduces the deleterious effects of a disease state in mammals, including humans.
- 30 The specific dose of a compound administered according to this invention to obtain therapeutic or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered,

-28-

the route of administration and the condition being treated. Typical daily doses will contain a pharmaceutically effective amount typically in the range of from about 0.0001 mg/kg/day to about 50 mg/kg/day of body weight of an active compound of this invention. Preferably the dose of compounds of the invention will be from 0.0001 to 5 mg/kg/day of body weight.

Preferably compounds of the invention (e.g., per Formula I) or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a mammal. The unit dosage form can be a capsule or tablet itself, or the appropriate number of any of these. The quantity of Active ingredient in a unit dose of composition may be varied or adjusted from about 0.0001 to about 1000 milligrams or more according to the particular treatment involved. It may be appreciated that it is necessary to make routine variations to the dosage depending on the age and condition of the patient. Dosage will also depend on the route of administration. The compounds of the invention may be administered by a variety of routes including oral, aerosol, rectal, transdermal, sublingual, subcutaneous, intravenous, intramuscular, and intranasal. Particularly preferred is the treatment of psoriasis with an ointment type formulation containing the compounds of the invention. The ointment formulation may be applied as needed, typically from one to 6 times daily.

Treatment of psoriasis is preferably done with topical application by a formulation in the form of a cream, oil, emulsion, paste or ointment containing a therapeutically effective amount of a compound of the invention.. The formulation for topical treatment contains from 0.5 to 0.00005 weight percent, preferably from .05 to 0.0005 weight percent, and most preferably from 0.025 to 0.001 of a Active Ingredient.

For example, two semisolid topical preparations useful as vehicles for VDR modulators in treatment and prevention of psoriasis are as follows:

Polyethylene Glycol Ointment USP (p. 2495)

Prepare Polyethylene Glycol Ointment as follows:

Polyethylene Glycol 3350	400 g.
Polyethylene Glycol 400	<u>600 g.</u>
To make	1000 g.

Heat the two ingredients on a water bath to 65C. Allow to cool, and stir until congealed. If a firmer preparation is desired, replace up to 100 g of

-29-

the polyethylene glycol 400 with an equal amount of polyethylene glycol 3350.

Hydrophilic Ointment USP (p. 1216)

Prepare Hydrophilic Ointment as follows:

5	Methylparaben	0.25 g.
	Propylparaben	0.15 g.
	Sodium Lauryl Sulfate	10 g.
	Propylene Glycol	120 g.
	Stearyl Alcohol	250 g.
10	White Petrolatum	250 g.
	Purified Water	<u>370 g.</u>
	To make about	1000 g.

The Stearyl Alcohol and White Petrolatum are melted on a steam bath, and warmed to about 75C. The other ingredients, previously dissolved in the water are added, 15 warmed to 75C, and the mixture stirred until it congeals.

For each of the above formulations the Active Ingredient is added during the heating step in an amount that is from 0.5 to 0.00005 weight percent, preferably from .05 to 0.0005 weight percent, and most preferably from 0.025 to 0.001 weight percent of the total ointment weight. (Source: - United States Pharmacopoeia 24, United States 20 Pharmacopeial Convention, 1999)

Conventional therapy for osteoporosis includes; (i) estrogens, (ii) androgens, (iii) calcium supplements, (iv) vitamin D metabolites, (v) thiazide diuretics, (vi) calcitonin, (vii) bisphosphonates, (viii) SERMS, and (ix) fluorides (see, Harrison's Principles of Internal Medicine, 13th edition, 1994, published by McGraw Hill Publ., ISBN 0-07-25 032370-4, pgs.2172-77; the disclosure of which is incorporated herein by reference.). Any one or combination of these conventional therapies may be used in combination with the method of treatment using compounds of Formulae I as taught herein. For example, in a method of treating osteoporosis, the vitamin D receptor modulator compounds of the invention (e.g., as defined by formula I) may be administered separately or simultaneously 30 with a conventional therapy. Alternatively, the vitamin D receptor modulator compounds of the invention may be combined with conventional therapeutic agents in a formulation for treatment of osteoporosis such as set out below:

-30-

A formulation for treating osteoporosis comprising:

Ingredient (A1): a vitamin D receptor modulator represented by formula (I), or a pharmaceutically acceptable salt or prodrug derivative thereof;

5 Ingredient (B1):

one or more co-agents that are conventional for treatment
osteoporosis selected from the group consisting of:

- a. estrogens,
- b. androgens,
- c. calcium supplements,
- d. vitamin D metabolites,
- e. thiazide diuretics,
- f. calcitonin,
- g. bisphosphonates,
- h. SERMS, and
- i. fluorides; and

10 Ingredient (C1): optionally, a carrier or diluent.

Typically useful formulations are those wherein the weight ratio of (A1) to (B1) is from
10:1 to 1:1000 and preferably from 1:1 to 1:100.

15

Combination Therapy for Psoriasis:

Conventional therapy for psoriasis includes topical glucocorticoids, salicylic acid,
crude coal tar, ultraviolet light, and methotrexate (see, Harrison's Principles of Internal
Medicine, 13th edition, 1994, published by McGraw Hill Publ., ISBN 0-07-032370-4,
20 pgs.2172-77). Any one or combination of these conventional therapies may be used in
combination with the method of treatment using compounds of Formulae I as taught
herein. For example, in a method of treating osteoporosis, the vitamin D receptor
modulator compounds of the invention (e.g., as defined by formula I) may be topically
administered separately or simultaneously with a conventional therapy. Alternatively, the
25 vitamin D receptor modulator compounds of the invention may be combined with
conventional therapeutic agents in a topically applied formulation for treatment of
30 osteoporosis such as set out below:

-31-

A formulation for treating psoriasis comprising:

Ingredient (A2): a vitamin D receptor modulator represented by formula (I), or a pharmaceutically acceptable salt or prodrug derivative thereof;

5 Ingredient (B2):

one or more co-agents that are conventional for treatment psoriasis selected from the group consisting of:

- a. topical glucocorticoids ,
- b. salicylic acid, or
- c. crude coal tar.

10 Ingredient (C2): optionally, a carrier or diluent.


Typically useful formulations are those wherein the weight ratio of (A2) to (B2) is from 1:10 to 1:100000 and preferably from 1:100 to 1:10000.

15

-32-


General Procedures

Scheme I




5

Scheme II.




-33-

Scheme III.




-34-

Scheme IV



-35-

Scheme V



General Procedures

Scheme I. To a furan-2-carboxylic acid is added lithium diisopropylamine (2-2.5 equivalents) from -80 to 0°C in diethylether or THF solvent under nitrogen. A substituted ketone is added and the mixture is brought to room temperature from 1 to 48 h. The 5 mixture is worked up from ether and water to give the carbinol A. The carbinol A. is reacted with an o-substituted phenol (0.9 to 5 equivalents) with a Lewis acid, e.g., boron trifluoride etherate (0.01 to 10 equivalents) at from 0° C to room temperature for 30 min to 48 h. The reaction is worked up from ether and water, removing excess phenol under vacuum to give diarylmethane B. Diarylmethane B. can be activated with an 10 alkylchloroformate and base such as trialkylamines followed by treatment with a substituted primary or secondary amine to give the amide C. Amide C. is alkylated with an α -haloketone in the presence of a base such as sodium hydroxide or potassium carbonate in a polar aprotic solvent to give the amide D. Reduction of amide D. with sodium or lithium borohydride or cyanoborohydride in lower molecular weight alkanols 15 gives the secondary carbinol E. as a racemate. The Racemates, of course, can be separated into enantiomers by chiral chromatography on, e.g., a ChiralPak AD column.

Scheme II. Alternately, the ester of diarylmethane B. can be generally prepared as follows: A furanyl carboxylate is reacted with an alkyl magnesium bromide or alkyl lithium (2.0 to 20 2.5 equivalents) at from 0° C to room temperature in ether or THF solvent over 30 min to 48 h to give the tert-carbinol F. The tert-carbinol F. is deprotonated with of an alkyl lithium reagent (1.9 to 2.5 equivalents) at from -80 °C to 0 °C over a period of 10 min to 2 h, then excess carbon dioxide gas is bubbled into the mixture, and the mixture is allowed to come to room temperature from 30 min to 48 h. The mixture is worked up 25 from water and ether to give the carboxylic acid A. The carboxylic acid A. may be simultaneously dehydrated and esterified by heating with an alkanol saturated with hydrogen halides such as hydrogen chloride or hydrogen bromide to give the Z/E-olefin G. The olefin G. like carbinol A. may alkylate a substituted o-phenol in the presence of a Lewis acid, e.g., boron trifluoride etherate (0.01 to 5 equivalents) to give the ester of B, 30 which can be saponified from room temperature to reflux in an alkanol with sodium, potassium, or lithium hydroxide to B.

-37-

Scheme III. To a 4-hydroxy-3-alkyl benzoate ester is added alkylmagnesium halide in a reaction analogous to Scheme II, product F. to give the tert-carbinol H. The phenolic H intermediate is alkylated with an alpha-halo ketone or alpha-halo ester in a reaction analogous to Scheme I, product D. to give the intermediate I. Reacting I. with a substituted or unsubstituted furan in the presence of a Lewis acid, such as, boron trifluoride etherate at room temperature for 30 min to 60 h gives the diarylmethane J. The diarylmethane J. is reacted with an excess of Grignard reagent, analogous to the reaction in Scheme II, product F. to produce the intermediate tert-carbinol K. Treatment of carbinol K. with an alkylolithium in a reaction analogous to Scheme II, product A. gives the acid L. The acid L. is coupled with a primary or secondary amine in the presence of a coupling reagent, such as, EDCI/HOAT in a polar aprotic solvent, such as, DMF to give the amide M.

Scheme IV: The synthesis of carbon linked acetylenic carbinols S is also described in Scheme IV. The starting material N. is produced from Scheme III intermediate H. and a substituted or unsubstituted furan in the presence of Lewis acid, analogous to the synthesis of Scheme III, product J. Furan N. is reacted with triflic anhydride in a chlorocarbon solvent and trialkylamine base over 30min to 48 h to give the triflate O. The triflate O. is coupled to TMS-acetylene with palladium in the present of a base, such as CsF or trialkylamine in DMF or acetonitrile/water solvent over 30 min to 48 h from room temperature to 110 ° C. to produce the acetylene P. Acetylene P. is de-protonated and reacted with a dialkyl ketone or aldehyde to produce the secondary or tert-carbinol Q. The carbinol Q. in reactions analogous to Scheme III, acid L. and amide M. is used to produce the intermediate acid R. and amide S.


Scheme V. The bis-pinacolone T. can be formed by reacting a diaryl B. with t-butyl carbonyl chloride (2.0 to 2.5 equivalents) in the presence of potassium iodide (0.01 to 0.10 equivalents), K_2CO_3 (4 to 5 equivalents) and cyanomethane at reflux from about 2 to about 6 hours. The bis-pinacolone T. is dealkylated with a suitable base such as sodium hydroxide (4 to 6 equivalents) in the presence of a suitable solvent such as a methanol/ H_2O mixture to provide the pinacolone-acid U. The N-alkyl amide V. can be prepared by activating the pinacolone-acid U. with thionyl chloride in the presence of a

-38-


suitable amine, such as pyridine and subsequently reacted with a suitable alkyl amine in a suitable organic solvent.

Example 1

- 5 Preparation of 3'-[4-(2-oxo-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane.



A. 3'-(5-Carboxy-2-furyl)-3'-hydroxypentane.




10

- To a solution of i-propylamine (44.8 mL, 0.32 mole) in THF (980 mL) is added 1.6 M n-butyllithium (200 mL, 0.32 mole) in hexanes at -15 to -8 °C. with stirring. The mixture is diluted with THF (640 mL) and cooled to -74 °C. The 2-furoic acid (17.92 g, 0.16 mole) in THF (320 mL) is added so as to keep the temperature at -70 to -77 °C. After 30 min in the cold, 3-pentanone (15.15 g, 0.176 mole) in THF (20 mL) is added dropwise while keeping the temperature below -70 °C., and then the reaction mixture is allowed to come to room temperature. The mixture is quenched with water, and most of the THF is removed by evaporation under vacuum. The aqueous residue is extracted with diethylether (2 x 200 mL) and acidified with 5N HCl. The product is extracted with diethylether (3 x 600 mL), MgSO₄ dried, concentrated, to give the title compound as an oil (31.3 g, 99% crude) which is used as is.


-39-

B. 3'-[4-Hydroxy-3-methylphenyl]-3'-[5-carboxy-2-furanyl]pentane.



- 5 To 3'-(5-carboxy-2-furanyl)-3'-hydroxypentane (5.94 g, 30 mmol) and o-cresol (19.44 g, 180 mmol) in methylene chloride (30 mL) is added borontrifluoride etherate (1.5 mL, 12 mmol) at room temperature under nitrogen. The mixture is stirred for 5 h, and the mixture is partitioned between diethylether (100 mL) and satd sodium carbonate (100 mL). The aqueous phase is washed one more time with diethylether (100 mL). The combined ether layers are extracted twice with satd sodium carbonate (2 x 30 mL), and the combined aqueous phases are washed with diethylether (2 x 50 mL) prior to acidification with 5N HCl to pH ~2. The product is extracted into diethylether (2 x 100 mL), dried over MgSO₄, and evaporated under vacuum to give an oil. The residue is crystallized from ethylacetate and isoctane to give the title product as white crystals (5.33 g, 62%).
- 10 ES/MS: 289.0 (M+1).
- 15
- 20
- ¹H NMR (CDCl₃) δ 9.12 (s, 1H), 7.13 (d, 1H, J = 3.6 Hz), 6.80 (s, 1H), 6.75 (d, 1H, J = 8.2 Hz), 6.68 (d, 1H, J = 8.2 Hz), 6.36 (d, 1H, J = 3.6 Hz), 2.06 (s, 3H), 1.97 (q, 4H, J = 7.0), 0.60 (t, 6H, J = 7.0 Hz).

C. 3'-(4-Hydroxy-3-methylphenyl)-3'-(5-dimethylaminocarbonyl-2-furanyl)pentane.



- To 3'-(4-hydroxy-3-methylphenyl)-3'-(5-carboxy-2-furanyl)pentane (0.75 g, 2.6 mmol) in THF (50 mL) is added tri-n-butylamine (0.67 mL, 2.86 mmol), and the mixture is cooled in an ice bath. To the cooled solution is added isobutylchloroformate (0.372 mL, 2.86 mmol) dropwise, and it is allowed to stir 5 min. To the

-40-

mixture is added 2.0 M dimethylamine in methanol (7.8 mL, 15.6 mmol) and the reaction is allowed to come to room temperature and stirred 30 min. The mixture is evaporated under vacuum, and the residue is partitioned between water (100 mL) and diethylether (100 mL). The organic phase is washed with satd sodium bicarbonate (2 x 5 mL); with satd brine (30 mL); with 0.3 N HCl (3 x 30 mL); and with satd brine (10 mL). The organic phase is dried over MgSO₄, and evaporated under vacuum to give the title product as an oil (538 mg, 66%)
ES/MS: 316.3 (M+1), 314.2 (M-1).


10 D. 3'-[4-(2-Oxo-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane.

To 3'-[4-hydroxy-3-methylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane (0.53 g, 1.7 mmol) in acetonitrile (15 mL) is added 1-chloropinacolone (0.23 mL, 1.76 mmol), potassium carbonate (1.16 g, 8.4 mmol), and catalytic potassium iodide (14 mg, 0.08 mmol). The mixture is heated at reflux for 45 min; cooled to room temperature; and evaporated under vacuum. The residue is partitioned between methylene chloride and water, and the water layer is extracted one time more with methylene chloride. The combined organic layers are dried over anhydrous magnesium sulfate, filtered, and evaporated under vacuum to give an oil. The residue is crystallized from hexane to give the title compound (0.41 g, 59%)
¹H NMR (CDCl₃) δ 6.92 (m 2H), 6.84 (d, 1H, J = 8.0 Hz), 6.62 (d, 1H, J = 8.0 Hz), 6.41 (d, 1H, J = 3.0 Hz), 5.07 (s, 2H), 2.92 (s, 6H), 2.15 (s, 3H), 2.00 (q, 4H, J = 7.6 Hz), 1.16 (s, 9H), 0.61 (t, 6H, J = 7.6 Hz).
25 ES/MS: 414.2 (M+1).

-41-

Example 2

Preparation of 3'-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane.



5


- 3'-(4-(2-Oxo-3,3-dimethylbutoxy)-3-methylphenyl)-3'-(5-dimethylaminocarbonyl-2-furanyl)pentane (0.32 g, 0.79 mmol) and sodium borohydride (30 mg, 0.79 mmol) are combined in methanol (30 mL) at ambient temperature and allowed to stir at room temperature overnight. Acetone (1 mL) is added, and mixture is evaporated under vacuum. The residue is partitioned between methylene chloride and water, and the water layer is extracted with methylene chloride twice more. The combined organic extracts are dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum to give the title product as a colorless oil (0.325 g, 99%).
- 10 ^1H NMR (CDCl_3) δ 7.01 (d, 1H, J = 3.3 Hz), 6.92 (m, 2H), 6.73 (d, 1H, J = 8.3 Hz), 6.26 (d, 1H, J = 3.6 Hz), 5.30 (s, 1H), 4.08 (d, 1H, J = 7.2 Hz), 3.86 (t, 1H, J = 7.2 Hz), 3.84 (d, 1H, J = 7.2 Hz), 3.04 (s, 6H), 2.20 (s, 3H), 2.04 (m, 4H), 1.03 (s, 9H), 0.72 (t, 6H, J = 7.0 Hz).
- 15 ES/MS: 416.2 (M+1).

20

-42-

Example 3 and Example 4

Preparation of enantiomers 3'-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane.



5 A mixture of racemic 3'-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane, Example 2 (300 mg), is chromatographed on a ChiralPak AD column with 40:60 IPA/hexane to give enantiomer 1, Example 3 (110 mg, 37%) and enantiomer 2, Example 4 (110 mg, 37%).

10 Enantiomer 1, Example 3


HPLC: ChiralPak AD (4.6X250 mm); 0.1% TFA/40% IPA/60% heptane; 1 ml/m (flow rate); Rt = 5.6 m
NMR eq. To Example 2.

15 Enantiomer 2, Example 4

HPLC: ChiralPak AD (4.6X250 mm); 0.1% TFA/40% IPA/60% heptane; 1 ml/m (flow rate); Rt = 8.6m


Example 5

20 Preparation of 3'-[4-(2-oxo-3,3-dimethylbutoxy)-3-(2-butyl)phenyl]-3'-[5-dimethylaminocarbonyl-furan-2-yl]pentane.



-43-


A. 3-(2-Furanyl)pentan-3-ol



2-methyl furate (10.0 g, 79 mmol) is dissolved in THF (100 mL) under a nitrogen atmosphere. Ethyl magnesium bromide (3.0 M in Et₂O, 55 ml, 166 mmol) is added initially at room temperature. The reaction is cooled to -30 °C, and the remaining ethyl Grignard added. The mixture is stirred overnight at room temperature. Saturated sodium bicarbonate solution (10 mL) is added to the stirring solution followed by diethyl ether (100 mL) and water (50 mL). The organic layer is separated and washed with water. The ether layer is dried over magnesium sulfate, filtered, and evaporated under vacuum to give 10.7 g of a oil, which was used without further purification.

¹H NMR (CDCl₃) δ 7.37 (s, 1H), 6.31 (d, 1H), 6.18 (d, 1H), 1.83 (m, 4H), 0.88 (t, 6H).

B. 3-(5-Carboxy-2-furanyl)pentan-3-ol




3-(2-Furanyl)pentan-3-ol (3.0 g, 19mmol) is added to THF (20 mL) under a nitrogen atmosphere. The solution is stirred and cooled to -78 °C. Sec-BuLi (1.3 M in cyclohexane, 31 mL, 41 mmol) is added dropwise maintaining the temperature below -55 °C. After complete addition, the ice bath is removed and the solution slowly warmed to room temperature where it is stirred for 18 hours. The mixture is cooled to -48 °C and CO₂ gas is bubbled through the solution. A thick yellow past results and the temperature is increased to -10 °C. Water (50 mL) is added and the solution is stirred at room temperature for 30 minutes. Ethyl acetate is added followed by water and the pH is adjusted to 1 with 1 N HCl. The organic layer is separated and the water layer was discarded. The organic layer is added to 1N NaOH solution and extracted. The pH of the water layer is adjusted to 1 with 1N HCl followed by addition of EtOAc. The organic layer is separated, dried over sodium sulfate, filtered, and evaporated under vacuum to give 2.7 grams of an oil.

-44-

¹H NMR (CDCl₃) δ 8.5-10.0 (br, 1H), 7.22 (d, 1H), 6.40 (d, 1H), 1.88 (m, 5H), 1.80 (t, 6H).


C. Z/E-3-(5-Methoxycarbonyl-2-furanyl)pent-2-ene



5 3-(5-Carboxy-2-furanyl)pentan-3-ol (200 mg, 1.1 mmol) is dissolved in methanol (20 mL). HCl (g) is bubbled through the solution for 30 seconds. The reaction is stirred for 20 minutes at room temperature with no reaction. The solution is heated to 60 °C for 2 hours. The solution is concentrated and water is added followed by solid NaHCO₃ until
10 the pH was basic. Ethyl acetate is added and the solution is extracted. The organic layer is washed with water, dried over MgSO₄ and filtered. The filtrate is concentrated to 213 mg of an orange oil which is used as is.

15 ¹H NMR (CDCl₃) δ 6.35 (q, 0.95 H, J = 6.8 Hz, E-isomer), 5.72 (q, 0.05 H, J = 6.8 Hz, Z-isomer). Irradiation of major isomer methyl doublet (1.83 ppm) produced a significant nuclear Overhauser effect upon the methylene quartet of the major isomer (2.40 ppm) as well as the vinyl H of the major isomer (6.35 ppm) confirming the major isomer as E.

D. 3'-[4-Hydroxy-3-(2-butyl)phenyl]-3'-(5-methoxycarbonyl-furan-2-yl)pentane.




20 To Z/E-3-(5-methoxycarbonyl-2-furanyl)pent-2-ene (0.97 g, 5 mmol) in 2-(2-butyl)phenol (3.75 g, 25 mmol) is added boron trifluoride etherate (213 mg, 1.5 mmol) in methylene chloride (0.5 mL), and the mixture is stirred for 9 d at room temperature. The mixture is partitioned between diethyl ether and water, and the organic phase is washed twice more with water, once with satd brine, and dried over anhydrous sodium sulfate. The solvent is evaporated under vacuum, and the residue is chromatographed on 12 g of

-45-

silica gel with a step gradient from 4% ethylacetate in hexanes to 6% ethylacetate in hexanes to give the title compound (1.12 g, 65%).


¹H NMR (CDCl₃) δ 7.10 (d, 1H, J = 3.6 Hz), 6.93 (s, 1H), 6.82 (d, 1H, J = 8.4 Hz), 6.22 (d, 1H, J = 3.6 Hz), 4.56 (s, 1H), 3.82 (s, 3H), 2.91 (m, 1H), 1.97-2.19 (m, 4H), 1.59 (m, 5 H), 1.19 (d, 3H, J = 6.8 Hz), 0.82 (t, 3H, J = 7.2 Hz), 0.69 (t, 6H, J = 7.4 Hz).
ES/MS: 345.3 (M+1), 343.3 (M-1).

E. 3'-[4-Hydroxy-3-(2-butyl)phenyl]-3'-[5-carboxyl-furan-2-yl]pentane.



To 3'-[4-hydroxy-3-(2-butyl)phenyl]-3'-[5-methoxycarbonyl-furan-2-yl]pentane (0.2 g, 0.6 mmol) in methanol (5 mL) is added 5N NaOH (232 uL, 11.2 mmol), and the mixture is heated at 70 °C. for 1.5 h in an open flask. Water is intermittently added to replace the evaporated methanol. The mixture is cooled to rt, and made acidic to pH paper with 5 N HCl. The product is extracted into methylene chloride, dried over anhydrous sodium sulfate, and evaporated to give the title compound (0.165 g, 87%).
¹H NMR (CDCl₃) δ 6.93 (d, 1H, J = 2.4 Hz), 6.82 (d, 1H, J = 8.4 Hz), 6.64 (d, 1H, J = 8.4 Hz), 6.26 (d, 1H, J = 3.6 Hz), 4.56 (s, 1H), 2.91 (m, 1H), 1.97-2.19 (m, 4H), 1.59 (m, 2H), 1.18 (d, 3H, J = 6.8 Hz), 0.82 (t, 3H, J = 7.2 Hz), 0.69 (t, 6H, J = 7.2 Hz).
Exact mass: 331.192, calcd. 331.1909 for C₂₀H₂₇O₄.

F. 3'-[4-Hydroxy-3-(2-butyl)phenyl]-3'-[5-dimethylaminocarbonyl-furan-2-yl]pentane.



To 3'-[4-hydroxy-3-(2-butyl)phenyl]-3'-[5-carboxyl-furan-2-yl]pentane (0.164 g, 0.5 mmol) in DMF (0.5 mL) is added EDCI (120 mg, 0.6 mmol), 0.5 M HOAt in DMF

-46-

(1.24 mL, 0.6 mmol), triethylamine (250 mg, 2.5 mmol), and dimethylamine hydrochloride (50 mg, 0.6 mmol). The mixture is stirred at rt for 64 h and partitioned between methylene chloride and satd sodium bicarbonate. The organic layer is dried over anhydrous sodium sulfate and evaporated. The residue is chromatographed on 4g of silica gel with a step gradient from 20% ethylacetate in hexanes to 25% ethylacetate in hexanes to give the title compound (80 mg, 45%).

5 ^1H NMR (400 mHz, CDCl_3) δ 7.01 (d, 1H, $J = 3.6$ Hz), 6.92 (s, 1H), 6.79 (d, 1H, $J = 8.4$ Hz), 6.63 (d, 1H, $J = 8.4$ Hz), 6.24 (d, 1H, $J = 3.6$ Hz), 4.91 (s, 1H), 3.03 (s, 6H), 2.92 (m, 1H), 1.97-2.05 (m, 4H), 1.52-1.63 (m, 2H), 1.18 (d, 3H, $J = 7.2$ Hz), 0.82 (t, 3H, $J = 7.2$ Hz), 0.70 (t, 6H, $J = 7.2$ Hz).

10 LC/MS: 358.3 (M+1), 356.3 (M-1).

G. 3'-(4-(2-Oxo-3,3-dimethylbutoxy)-3-(2-butyl)phenyl]-3'-(5-dimethylaminocarbonyl-furan-2-yl]pentane.

15


Using a procedure analogous to Example 1D, 3'-(4-hydroxy-3-(2-butyl)phenyl]-3'-(5-dimethylaminocarbonyl-furan-2-yl]pentane (80 mg, 0.22 mmol) is reacted with 1-chloropinacolone to give the title compound as an oil (90 mg, 90%). to give the title compound (80 mg, 45%).

20 ^1H NMR (400 mHz, CDCl_3) δ 7.01 (d, $J = 3.6$ Hz, 1H), 6.97 (s, 1H), 6.84 (d, $J = 8.4$ Hz, 1H), 6.25 (d, $J = 3.6$ Hz, 1H), 4.82 (s, 2H), 3.03 (s, 6H), 3.14 (m, 1H), 1.98-2.12 (m, 4H), 1.48-1.64 (m, 2H), 1.25 (s, 9H), 1.17 (d, $J = 7.2$ Hz, 3H), 0.81 (t, $J = 7.2$ Hz, 3H), 0.70 (t, $J = 7.2$ Hz, 6H).

ES/MS: 456.3 (M+1).

25

In procedures analogous to those above, the following examples are prepared:



-47-

Example No.	Oxo/Carbinol Rac/isomer	R1	R2	R3	R4
6	Oxo	Ethyl	H	Methyl	H
7	Oxo	Ethyl	Ethyl	Methyl	H
8	Oxo	Methyl 1	Methyl	Methyl	4-methyl
9	Racemate	Methyl 1	Ethyl	Methyl	H
10	Isomer 1	Methyl 1	Methyl	Ethyl	H
11	Isomer 2	Methyl 1	Methyl	Ethyl	H
12	Isomer 1	Methyl 1	Methyl	n-propyl	H
13	Isomer 1	Methyl 1	Methoxy	Ethyl	H

Example	Name	Physical Data
6	3'-[4-(2-oxo-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-ethylaminocarbonyl-2-furanyl]-pentane	¹ H NMR (300 mHz, DMSO-d ₆) δ 8.09 (m, 1H), 6.98 (d, J = 3.2 Hz, 1H), 6.94 (s, 1H), 6.86 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 6.40 (d, J = 3.2 Hz, 1H), 5.09 (s, 2H), 3.19 (m, 2H), 2.18 (s, 3H), 1.95-2.10 (m, 4H), 1.18 (s, 9H), 1.03 (t, J = 7.0 Hz, 3H), 0.60 (t, J = 7.0 Hz, 6H). ES/MS: 414.3 (M+1).
7	3'-[4-(2-oxo-3,3-dimethylbutoxy)-3-methylphenyl]-3'-	¹ H NMR (CDCl ₃) δ 7.00 (d, J = 3.2 Hz, 1H), 6.90 (s, 1H), 6.88

-48-

	[5-diethylaminocarbonyl-2-furanyl]-pentane	(d, J = 8.4 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 6.26 (d, J = 3.2 Hz, 1H), 4.83 (s, 2H), 3.37 (m, 4H), 2.24 (s, 3H), 1.95-2.10 (m, 4H), 1.24 (s, 9H), 1.15 (m, 3H), 1.95 (m, 3H), 0.68 (t, J = 7.2 Hz, 6H). Exact Mass: calcd for C ₂₇ H ₄₀ NO ₄ (M+1) 442.2957, found 442.2950.
8	3'-[4-(2-oxo-3,3-dimethyl-butoxy)-3-methylphenyl]-3'-[5-dimethylaminocarbonyl-3-methyl-2-furanyl]-pentane	¹ H NMR (300 mHz, CDCl ₃) δ 6.95 (s, 1H), 6.90 (d, J = 9.0 Hz, 1H), 6.52 (d, J = 9.0 Hz, 1H), 6.13 (s, 1H), 4.85 (s, 2H), 2.98 (s, 6H), 2.50 (s, 3H), 2.46 (s, 3H), 1.95-2.12 (m, 4H), 1.27 (s, 9H), 0.70 (t, J = 7.2 Hz, 6H). ES/MS: 428.4 (M+1).
9	3'-[4-(2-hydroxy-3,3-dimethyl-butoxy)-3-methylphenyl]-3'-[5-N-ethyl-N-methylamino-carbonyl-2-furanyl]pentane	¹ H NMR (CDCl ₃) δ 7.00 (d, J= 3.2 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.90 (s, 1H), 6.70 (d, J = 8.8 Hz, 1H), 6.25 (d, J = 3.2 Hz, 1H), 4.06 (d, J = 8.8 Hz, 1H), 3.84 (t, J = 9.0 Hz, 1H), 3.70 (d, J = 8.8 Hz, 1H), 3.40 (m, 2H), 2.98 (m, 3H), 2.44 (s, 1H), 2.18 (s, 3H), 1.98-2.10 (m, 4H), 1.10 (m, 3H), 1.02 (s, 9H), 0.68 (t, J = 7.2 Hz, 6H). ES/MS: 430.2 (M+1).
10	3'-[4-(2-hydroxy-3,3-	¹ H NMR (CDCl ₃) δ 7.00 (d, J=

-49-


	dimethyl-butoxy)-3-ethylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane enantiomer 1	¹ H NMR (CDCl ₃) δ 7.00 (d, J = 3.2 Hz, 1H), 6.92 (m, 2H), 6.71 (d, J = 8.8 Hz, 1H), 6.25 (d, J = 3.2 Hz, 1H), 4.08 (d, J = 8.8 Hz, 1H), 3.85 (t, J = 8.8 Hz, 1H), 3.70 (d, J = 8.8 Hz, 1H), 3.04 (s, 6H), 2.59 (q, J = 8.0 Hz, 2H), 2.41 (m, 1H), 1.98-2.13 (m, 4H), 1.14 (t, J = 7.4 Hz, 3H), 1.01 (s, 9H), 0.70 (t, J = 7.4 Hz, 6H). ES/MS: 430.2 (M+1), 447.2 (M+NH ₄).
11	3'-[4-(2-hydroxy-3,3-dimethyl-butoxy)-3-ethylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane enantiomer 2	¹ H NMR (CDCl ₃) δ 7.00 (d, J = 3.2 Hz, 1H), 6.92 (m, 2H), 6.71 (d, J = 8.8 Hz, 1H), 6.25 (d, J = 3.2 Hz, 1H), 4.08 (d, J = 8.8 Hz, 1H), 3.85 (t, J = 8.8 Hz, 1H), 3.70 (d, J = 8.8 Hz, 1H), 3.04 (s, 6H), 2.59 (q, J = 8.0 Hz, 2H), 2.41 (m, 1H), 1.98-2.13 (m, 4H), 1.14 (t, J = 7.4 Hz, 3H), 1.01 (s, 9H), 0.70 (t, J = 7.4 Hz, 6H).
12	3'-[4-(2-hydroxy-3,3-dimethyl-butoxy)-3-n-propyl-phenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane enantiomer 1	¹ H NMR (CDCl ₃) δ 7.00 (d, J = 3.2 Hz, 1H), 6.92 (m, 2H), 6.72 (d, J = 8.8 Hz, 1H), 6.25 (d, J = 3.2 Hz, 1H), 4.08 (d, J = 8.8 Hz, 1H), 3.85 (t, J = 8.8 Hz, 1H), 3.70 (d, J = 8.8 Hz, 1H), 3.02 (s, 6H), 2.54 (t, J = 7.0 Hz, 2H), 2.39 (m, 1H), 1.98-2.13 (m,

-50-

		4H), 1.55 (m, 2H), 1.12 (m, 1H), 1.01 (s, 9H), 0.88 (t, J = 7.0 Hz, 3H), 0.70 (t, J = 7.2 Hz, 6H). ES/MS: 443.3 (M+1), 461.3 (M+NH ₄).
13	3'-[4-(2-hydroxy-3,3-dimethyl-butoxy)-3-ethylphenyl]-3'-[5-N-methoxy-N-methylamino-carbonyl-2-furanyl]pentane enantiomer 1	¹ H NMR (CDCl ₃) δ 7.09 (d, J = 3.2 Hz, 1H), 6.96 (s, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.71 (d, J = 8.8 Hz, 1H), 6.25 (d, J = 3.2 Hz, 1H), 4.08 (d, J = 8.8 Hz, 1H), 3.85 (t, J = 8.8 Hz, 1H), 3.70 (d, J = 8.8 Hz, 1H), 3.60 (s, 3H), 3.26 (s, 3H), 2.59 (q, J = 7.2 Hz, 2H), 2.40 (d, J = 2.4 Hz, 1H), 2.0-2.19 (m, 4H), 1.14 (t, J = 7.0 Hz, 3H), 1.01 (s, 9H), 0.71 (t, J = 7.4 Hz, 6H). ES/MS: 446.2 (M+1).


Example 14

Preparation of 3'-[4-(2-hydroxy-2-ethylbutoxy)-3-methylphenyl]-3'-[5-dimethylaminocarbonyl-2-furanyl]pentane.



-51-

A. 3'-(4-Hydroxy-3-methyl-phenyl)-3'-pentanol.




To methyl, 4-hydroxy-3-methylbenzoate (21.8 g, 0.13 mol) in 200 mL of THF
5 is added 1.0 M ethylmagnesium bromide (433 mL, 0.43 mol) dropwise under nitrogen at ambient temperature. The mixture is stirred for 64 h and quenched with dilute sodium bicarbonate. The mixture is triturated with diethyl ether five times (5x), and the combined organic layers are washed with dilute sodium bicarbonate, dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum to give the title
10 compound (27 g, 99%).

¹H NMR (400 MHz, CDCl₃) δ 7.29 (s, 1H), 7.04 (d, J = 8.4 Hz, 1H), 5.72 (d, J = 8.4 Hz, 1H), 4.74 (s, 1H), 3.75 (s, 1H), 2.26 (s, 3H), 1.82 (m, 4H), 0.76 (t, J = 7.6 Hz, 6H).

ES/MS: 193.2 (M-1).

15

B. 3'-(4-Methoxycarbonylmethoxy-3-methyl-phenyl)-3'-pentanol.




To 3'-(4-hydroxy-3-methyl-phenyl)-3'-pentanol (1.5 g, 7.7 mmol) in 20 mL of acetonitrile is added methyl, bromoacetate (0.73 mL, 7.7 mmol), potassium carbonate
20 (4.26 g, 31 mmol) and catalytic potassium iodide (~0.1 g). the mixture is heated at 80 ° C. for 6 hr. The mixture is cooled and the solvent evaporated under vacuum. The residue is partitioned between diethylether and water. The organic layer is wased with water four times (4x), dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum to give the title compound (2.06 g, 99%).

25 ¹H NMR (400 MHz, CDCl₃) 7.14 (s, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 4.64 (s, 2H), 3.80 (s, 3H), 2.30 (s, 3H), 1.80 (m, 4H), 0.76 (t, J = 7.4 Hz, 6H).

-52-

C. 3'-(4-Methoxycarbonylmethoxy-3-methyl-phenyl)-3'-(2-furanyl)pentane.




To 3'-(4-methoxycarbonylmethoxy-3-methyl-phenyl)-3'-pentanol (2.0 g, 7.7 mmol) in furan (25 mL) is added boron trifluoride etherate (0.39 mL, 0.3 mmol) at ambient temperature under nitrogen. The mixture is stirred for 4 hr, and quenched with satd. sodium bicarbonate. The product is extracted into diethylether, washed with water, satd. brine, dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum. The residue is chromatographed on 40g of silica gel with a gradient from 0-10 % ethylacetate in hexanes to give a fraction containing the title compound (1.3 g, 53%).

¹H NMR (400 MHz, CDCl₃) 7.28 (s, 1H), 6.95 (s, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 4.61 (s, 2H), 3.79 (s, 3H), 2.24 (s, 3H), 1.96-2.12 (m, 4H), 0.67 (t, J = 7.4 Hz).

ES/MS: 317.1 (M+1).

D. 3'-[4-(2-Hydroxy-2-ethylbutoxy)-3-methylphenyl]-3'-(2-furanyl)pentane.




To 3'-(4-methoxycarbonylmethoxy-3-methyl-phenyl)-3'-(2-furanyl)pentane (1.3 g, 4.1 mmol) in 10 mL of diethylether is added 1M ethylmagnesium bromide (10.2 mL, 10.2 mmol) dropwise, and the mixture is stirred over night. The mixture is quenched with sat sodium bicarbonate and triturated with diethylether five times (5x). The combined organic layers are washed with water, dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum to give the title compound (1.33 g, 94%).

-53-

¹H NMR (400 mHz, CDCl₃) 7.29 (s, 1H), 6.93 (m, 2H), 6.72 (d, J = 8.0 Hz), 6.29 (s, 1H), 6.18 (s, 1H), 3.79 (s, 2H), 2.20 (s, 3H), 1.16-2.12 (m, 4H), 1.66 (m, 4H), 0.93 (t, J = 7.4 Hz, 6H), 0.67 (t, J = 7.6 Hz, 6H).
ES/MS: 345.3 (M+1), 362.3 (M+NH4).

5

E. 3'-[4-(2-Hydroxy-2-ethylbutoxy)-3-methylphenyl]-3'-[5-carboxy-2-furanyl]pentane.



To 3'-[4-(2-hydroxy-2-ethylbutoxy)-3-methylphenyl]-3'-(2-furanyl)pentane

10 (1.3 g, 3.8 mmol) in 10 mL cyclohexane and 2 mL diethylether at 0-5 ° C. under nitrogen is added 1.3 M sec-buthyllithium (6.5 mL, 8.5 mmol). After 5 min, excess carbon dioxide gas is bubbled in, and the mixture is stirred for 2 h. The mixture is partitioned between diethylether and water. The aqueous phase is made acidic with 6N HCl, and the product is extracted into diethylether. The ether layer is washed with 15 water, dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum to give the title compound (0.66 g, 44%) which is used as is.

ES/MS: 387.3 (M-1), 406.3 (M+NH4).

F. 3'-(4-(2-Hydroxy-2-ethylbutoxy)-3-methylphenyl)-3'-(5-dimethylaminocarbonyl-2-furanyl)pentane.

To 3'-[4-(2-hydroxy-2-ethylbutoxy)-3-methylphenyl]-3'-(5-carboxy-2-furanyl)pentane (0.66 g, 1.7 mmol) is added EDCI (0.38 g 2.0 mmol), 0.5 M HOAT in DMF (3.4 mL, 1.7 mmol), and 2M dimethylamine in THF (1.7 mL, 3.4 mmol) in 25 DMF (2 mL). The mixture is stirred at room temperature for 2 h, and partitioned between diethylether and satd sodium bicarbonate. The organic layer is washed with water, satd brine, dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum. The residue is chromatographed on 10 g of silica gel with a gradient from 5-

-54-

30 % ethylacetate in hexane to give a fraction containing the title compound (0.16 g, 23%).

¹H NMR (400 MHz, CDCl₃) 7.00 (d, J = 3.6 Hz, 1H), 6.93 (d, J = 8.2 Hz, 1H), 6.90 (s, 1H), 6.70 (d, J = 8.2 Hz, 1H), 6.25 (d, J = 3.6 Hz, 1H), 3.79 (s, 2H), 3.04 (s, 6H), 2.19 (s, 3H), 2.06 (m, 4H), 1.67 (m, 4H), 0.93 (t, J = 7.4 Hz, 6H), 0.70 (t, J = 7.4 Hz, 6H).
ES/MS: 416.3 (M+1), 433.3 (M+NH4).

10

Table 1
Summary of Experimental Results
(Compounds of the Invention)

Test Cmpd. ¹	RXR-VDR heterodimer ² EC ₅₀ (nM)	VDR EC ₅₀ (nM) (Caco-2 cells) ³	OCN Promoter ⁴ EC ₅₀ (nM)	Mouse Hypercal ⁵ μg/Kg/dl
Ex. 1	3.3/0.6	191	5/3	>1500
Ex. 2		25	3	
Ex. 3	42/0.6	391	4.6/2.5	>2000
Ex. 4	10/0.5	333	2/1	>2000
Ex. 5	135/40	129	33/44	
Ex. 6	320	315	>1000	
Ex. 7			95	>9000
Ex. 8	156	758	125	
Ex. 9	16	616	30	
Ex. 10	13/0.1	191	1.6/0.5	>1000
Ex. 11	17.6	572	20	>3000
Ex. 12	188	187	0.5/0.1	
Ex. 13	18	572	20	>3000
Ex. 14	104	635	101	

-55-

Table 2
Summary of Experimental Results
(Compounds of the Invention)

Test Cmpd. ¹	Kera. Prolif. IC ₅₀ (nM)	IL-10. IC ₅₀ (nM)
Ex. 1	15	
Ex. 2		
Ex. 3	1	
Ex. 4	4	
Ex. 5	1000	
Ex. 6	112	
Ex. 7	23	
Ex. 8	>1000	
Ex. 9	28	
Ex. 10	7	
Ex. 11	18	
Ex. 12	17	
Ex. 13	18	4.6
Ex. 14	487/1000	

-56-

Table 3
Summary of Experimental Results
(Comparison Compounds)

Test Cmpd. ¹	RXR-VDR (SaOS-2 cells) ² EC ₅₀ (nM)	VDR CTF (Caco-2 cells) ³ EC ₅₀ (nM)	OCN Promoter ⁴ EC ₅₀ (nM)	Mouse Hypercal ⁵ µg/Kg/d
AA	5.02	16	5	0.06
BB	10.32	169.81	8.24	>=20
CC	2427.7		>1000	
DD	109.44		31.1	1000
EE	429.99	891.16	34.1.25	1000
FF	3	57		

5 Table 4

Summary of Experimental Results
(Comparison Compounds)

Test Cmpd. ¹	Kera. Prolif. IC ₅₀ (nM)	IL-10 IC ₅₀ (nM)
AA	120	1.2
BB	10	28
CC	-	-
DD	1060	
EE		
FF	103	0.5

Explanation of Tables 1, 2, 3, and 4:

- 10 Test Compound numbers refer to the products of the corresponding Example Nos. A slash mark “/” between numbers in a Table cell separates different experimental results obtained.
- The control experiments are done with the double letter coded compounds identified as follows:


-57-

“AA” = 1 α ,25-dihydroxyvitamin D₃


“BB” = 3-(4-{1-Ethyl-1-[4-(2-hydroxy-3,3-dimethyl-butoxy)-3-methyl-phenyl]-propyl}-2-methyl-phenoxy)-propane-1,2-diol “CC” = 1-(4-{1-[4-(3,3-Dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-cyclohexyl}-2-methyl-phenoxy)-3,3-dimethyl-butan-2-one

5

“DD” = compound represented by the formula:




“EE” = compound represented by the formula a:



10

calcipotriol (structural formula below):



2. The RXR-VDR heterodimerization (SaOS-2 cells) test is described in the
- 15 “Assay” section of the Description, infra.
3. The VDR CTF (Caco-2 cells) test is described in the “Assay” section of the Description, infra.
4. The OCN Promoter test is described in the “Assay” section of the Description, infra.
- 20 5. The Mouse Hypercalcemia test is described in the “Assay” section of the Description, infra.

-58-

6. The keratinocyte proliferation assay is described in the "Assay" section of the Description, infra.

7. The IL-10 induction assay is described in the "Assay" section of the Description, infra.

5

Assay Methods

Use of the Assay Methods:

The evaluation of the novel compounds of the invention for osteoporosis and other related diseases is done using a plurality of test results. The use of multiple assays is necessary since the combined properties of (i) high activity for the vitamin D receptor, and (ii) prevention of hypercalcemia must be achieved to have utility for the methods of treating diseases, which are also, aspects of this invention. Some of the tests described below are believed related to other tests and measure related properties of compounds. Consequently, a compound may be considered to have utility in the practice of the invention if it meets most, if not all, of the acceptance criteria for the above described tests.

The evaluation of the novel compounds of the invention for psoriasis is done using the Keratinocyte Proliferation Assay in combination with other assays that measure inhibition of IL-2 production and stimulation of IL-10 production in peripheral blood mononuclear cells (PBMCs).

Brief Description, Utility and Acceptance Criteria for the Assay Methods:

1. The RXR-VDR heterodimer Assay:

This assay provides the VDR activity of a test compound. It is desirable to have low EC₅₀ values for a compound in this assay. The lower the EC₅₀ value, the more active the compound will be as a VDR agonist. Desired assay results are EC₅₀ values less than or equal to 600 nM. Preferred assay results are less than 250 nM, and most preferably less than 150 nM.

-59-

2. The Caco-2 cell Co-transfection Assay:

The Caco-2 cell assay is an indicator for the undesirable condition of hypercalcemia. This co-transfection assay is a surrogate assay for in vivo calcemic activity of VDR ligands. It is desirable to have high EC50 values for a test compound 5 in this assay. The higher the EC50 values for a compound the less calcemic it will be in vivo. Desired assay results are EC50 greater than or equal to 300 nM. Preferred assay results are greater than 1000 nM.

3. The OCN (osteocalcin) Promoter Assay

10 The OCN Promoter Assay is an indicator and marker for osteoporosis. Desired assay results are EC50 less than or equal to 325 nM. Preferred assay results are less than 50 nM.

4. The Mouse Hypercalcemia Assay

15 The Mouse Hypercalcemia Assay is a six day hypercalcemia test for toxicity and selectivity. Acceptable test results are levels greater than 300 µg/kg/day. Preferred assay results are levels greater than 1000 µg/kg/day.

5. The Keratinocyte Proliferation Assay

20 This Assay is indicative for the treatment of psoriasis. An acceptable test result is IC50 value of less than or equal to 300 nM. Preferred assay results are IC50 values of less than 100 nM.

6. The IL-10 induction Assay

25 This is an in vitro efficacy assay for psoriasis, abscess and adhesion. Psoriasis involves both keratinocytes and immune cells. IL-10 is a unique cytokine because it is anti-inflammatory and immunosuppressive. This assay tells us whether a VDRM is able to function as an agonist in PBMCs (primary blood mononuclear cells) or not. A lower EC50 value is desirable in this assay since a compound with a lower EC50 value will be a 30 better agonist in PBMCs. An acceptable test result is an EC50 value of less than 200 nM. Preferred assay results are EC50 values of less than 100 nM.

-60-

7. Other Compound Assay Standards

An alternative measure of the efficacy of compounds of the invention for treatment of osteoporosis is a numerical ratio calculated as follows:

Dose Threshold needed to induce hypercalcemia

5 divided by

Dose Threshold needed for bone efficacy

An alternative measure of the efficacy of compounds of the invention for treatment of psoriasis is a numerical ratio calculated as follows:

10 Dose Threshold needed to induce hypercalcemia

divided by

Dose Threshold needed to induce keratinocyte proliferation

For the above ratios, Dose Thresholds are determined from dose response curve data.

15 8. The CaT1 (calcium transporter 1) Assay

The CaT1 Assay is an indicator for the undesirable condition of hypercalcemia. The higher the EC50 values for a compound the less calcemic it will be in vivo. Desired assay results are EC50 greater than or equal to 500 nM. Preferred assay results are greater than 1000 nM.

20

Details of the Assay Methods:

(1) Materials and Method for RXR-VDR Heterodimerization Assay:

Transfection Method:

- FuGENE 6 Transfection Reagent (Roche Cat # 1 814 443)

25 Growth Media:

- D-MEM High Glucose (Gibco BRL Cat # 11054-020), 10% FBS, 1% antibiotic-antimycotic (Ab-Am)

FBS heat inactivated (Gibco BRL Cat # 10092-147)

Ab-Am (Gibco BRL Cat # 15240-062)

30 Cells:

- Grow SaOs-2 cells in T-152 cm² culture flasks in *growth media*.
- Keep the density at 5-6 x 10⁵ cells/ml

-61-

- Passage cells 1:3 twice a week
- Add Trypsin EDTA (Gibco BRL Cat # 25300-020) and incubate
- Resuspend cells in plating media and transfer into growth media.

Wash Media:

- 5 • HBSS Low Glucose Without Phenol Red (Gibco BRL Cat # 14175-095), 1% Ab-Am

Plating Media:

- D-MEM Low Glucose Without Phenol Red (Gibco BRL Cat # 11054-020), 1% Ab-Am

D-MEM

Stripped FBS (Hyclone Cat# SH30068.03 Lot # AHM9371)

- 10 Ab-Am

Transfection / Treatment Media:

- D-MEM Low Glucose Without Phenol Red only

T-152 cm² culture flask:

- Use Corning Coastar T-152 cm² culture flask (Cat # 430825) to grow the cells

- 15 Flat well Plates:

- Use well plate to plate cells
- Use Deep well plate sterile to make up treatment media.

Luciferase Assay Reagent:

- 20 • Use Steady-Glo Luciferase Reagent from Promega (Cat # E2550) Consists of:

- a. E2533 Assay Substrate, lyophilized product and
- b. E2543 Assay Buffer.

- Thaw at room temperature
- Store

- 25 **DAY 1: Cell Plating:**

Cell Harvesting

Aspirate media from culture flask, rinse cells with HBSS and aspirate.

Add trypsin and incubate.

When cells appear detached, resuspend cells in *growth media*.

- 30 Transfer into a new flask with fresh *growth media* for passaging the cells.

Plate well plates and two extra plates

-62-

A. Cell Count

Mix the cell suspension using pipette

Use *Hematocytometer* to count the cells

Load cell suspension onto the hemocytometer chamber

5 Count cells.

Plate seeding:

Use plating media 10 % Stripped FBS in D-MEM Low Glucose, Without Phenol Red, 1%

Ab-Am

Plate 14 plates @ 165 µl / well.

10 In sterile flask add cell suspension
to *plating media*.

Mix .

Add cells / well.

Place the cells in the incubator.

15 Cells should be about 75 % confluent prior to transfection.

DAY 2: Transfection

Step 1: DNA and Media

Add plain DMEM media to tubes for mixing the DNA

Add the Reporter gene pFR-LUC

20 Add the Gal4-RXR-DEF and VP16-VDR-LBD

Step 2: FuGENE and Media

Prepare plain DMEM media in a tubes for mixing FuGENE

Add *FuGENE 6 Transfection Reagent*

25 Incubate

Step 3: FuGENE , DNA and Media Complex

Add FuGENE Media complex from step 2 to DNA Media complex from step 1

Incubate

30

Step 4: FuGENE , DNA and Media Complex to-well plate

Add FuGENE-DNA-Media complex from step 3 to each plate

-63-

Incubate.

DAY 3: Dosing

Treatment preparation

5 Allow for transfection time

Make a stock solution of the compounds in DMSO

Vortex until all the compounds has been dissolved.

Further dilute in D-MEM (Low Glucose – With out Phenol Red)

Add compounds in quadruplicate to give final volume

10 Incubate.

Day 4: Luciferase Assay

Read the plates after drug treatment

Remove part of media from all the wells and leave remainder

Add Steady-Glo Luciferase Reagent mixture / wells

15 Incubate

Count each well using a Luminescence counter, Top Count NXT by Packard

Set a delay between plates to reduce the background.

(2) Materials and Method for The Caco-2 Cell Assay:

20 Caco-2 cells, grown in phenol red free, DMEM (Invitrogen, Carlsbad, CA) containing 10 % charcoal-stripped FCS (Hyclone, Logan, UT), were transfected with Fugene 6 reagent (Roche Diagnostics, Indianapolis, IN). Cells (5000/well) were plated 18 h before transfection in a 96 well plate. The Cells were transfected with Gal4-responsive reporter pFRLuc (150 ng, Stratagene, La Jolla CA) and the receptor expression vector pGal4-VDR-LBD (10 ng), along with Fugene 6 reagent (0.2 µl/well). The DNA-Fugene complex was formed by incubating the mixture for 30 min at room temperature. The cells were transfected in triplicate for 5 h, and treated with various concentrations of VDR ligands (form 0.01 nM to 10,000 nM concentration range) 18h post-transfection. The luciferase activity

25 was quantified using Steady-Glo reagent kit (Promega, Madison, WI) as per manufacturer's specifications.

30

-64-

(3) Materials and Method for The OCN Promoter Assay:

The activation of osteocalcin by VDR ligands was evaluated in a rat
osteoblast-like cell line RG-15 (ROS 17/2.8) stably expressing rat osteocalcin
5 promoter fused with luciferase reporter gene. The stable cell lines were
established as reported before (Activation of Osteocalcin Transcription involves
interaction of protein kinase A- and Protein kinase C-dependent pathways.
Boguslawski, G., Hale, L. V., Yu, X.-P., Miles, R. R., Onyia, J. E., Santerre R.
F., Chandrasekhar, S. J Biol. Chem. 275, 999-1006, 2000). Confluent RG-15
10 cells maintained in DMEM/F-12 medium (3:1) containing 5% FBS, 300 µg/ml
G418 and at 37°C under 5% CO₂/95% air atmosphere were trypsinized.(0.25%
trypsin) and plated into white opaque 96-well cell culture plates (25000
cells/well). After 24 hr, cells (in DMEM/F-12 medium + 2% FBS) were treated
with various concentrations of compounds, dissolved in DMSO. The final
15 DMSO concentration remained at 0.01% (v/v). After 48 hr treatment, the
medium was removed, cells were lysed with 50 µl of lysis buffer (From
Luciferase reporter assay system, Roche Diagnostics, Indianapolis, IN) and
assayed for luciferase activity using the Luciferase Reporter Gene Assay kit from
Boehringer Mannheim as per manufacturer's specifications.

20

(4) Materials and Method for The Mouse Hypercalcemia Assay:

Weanling, virus -antibody-free, five to six weeks old female DBF mice (Harlan,
Indianapolis, IN) are used for all the studies. Animals are allowed to acclimate to local
vivarium conditions for 2 days. Mice are maintained on a 12 hr light/dark cycle at 22°C
25 with ad lib access to food (TD 5001 with 1.2% Ca and 0.9%P, Teklad, Madison, WI) and
water. The animals then are divided into groups with 4-5 mice per group. Different doses
of test compounds prepared in 10% Ethanol and 90% sesame oil are administered to mice
orally via gavage for 6 days. 1α-25(OH)₂D₃ 0.5µg/kg/d was also given to one group of
mice as the positive control. Serum ionized calcium is evaluated at 6 hours after the last
30 dosing under isoflurane anesthesia by Ciba-Corning Ca++/PH Analyzer, (Model 634,
Chiron Diagnostics Corp., East Walpole, MA). Raw data of group differences is assessed

-65-

by analysis of variance (ANOVA) using Fisher's protected least significant difference (PLSD) where the significance level was P< 0.05.

(5) The Keratinocyte Proliferation Assay:

5 KERtr cells (Human skin keratinocyte transformed with a retrovirus vector, obtained from ATCC) were plated in 96-well flat-bottomed plates (3000 cells/well) in 100 µl keratinocyte serum free medium supplemented with bovine pituitary extract in the absence of EGF (Life Technologies, Rockville, MD) and incubated at 37°C for two days. The cells were treated with various concentrations of VDR ligands (ten-fold serial
10 dilution from 10,000 nM to 0.1 nM in triplicate), dissolved in 100 µl keratinocyte serum free medium supplemented with bovine pituitary extract in the absence of EGF and incubated at 37°C for 72hr. BrdU (5-bromo-2'-deoxyuridine) incorporation was analyzed as a measure of DNA replication (Cell proliferation ELISA kit, Roche Diagnostics, Indianapolis, IN) and absorbance was measured at 405 nm. Potency values (IC₅₀) values
15 were determined as the concentration (nM) of compound that elicited a half-maximal response.

(6) Materials and Method for human IL-10 Induction Assay:

Isolation of peripheral blood mononuclear cells (PBMCs):

- A. Collect 50 ml of human blood and dilute with media, RPMI-1640.
- 20 B. Prepare sterile tubes with ficol.
- C. Add diluted blood to tubes.
- D. Centrifuge.
- E. Discard the top layer and collect the cells from middle layer.
- F. Divide all cells into four tubes and add media.
- 25 G. Centrifuge.
- H. Aspirate off media and resuspend.
- I. Collect all cells
- J. Centrifuge. at 1200 rpm for 10 minutes.
- K. Resuspend in RPMI-1640 with 2% FBS and count cells
- 30 Stimulation of PBMC:
 - L. Prepare TPA in DMSO.
 - M. Dissolve PHA in water .

-66-

N. Plate TPA/PHA treated PBMCs in well plates.

O. Incubate.

Treatment:

P. Prepare all compound dilutions in plain RPMI- 1640 media.

5 Q. Add diluted compound.

R. Incubate.

Sample Collection and assay:

S. Remove all the cells by centrifugation and assay the supernatant for IL-10 by immunoassay.

10 1) T. Perform IL-10 assay using anti-human IL-10 antibody coated beads, as described by the manufacturer (Linco Research Inc., St. Charles, MO).

(8) CaT1 assay

Human colon carcinoma, Caco-2 cells, maintained in DMEM (high glucose with
15 25 mM Hepes buffer; Invitrogen, Carlsbad, CA) supplemented with 10 % fetal bovine serum (Invitrogen, Carlsbad, CA), are plated at 5500 cell per well in a 96-well plate in a total volume of 100 µl/well. The cells are kept in the 96-well plate for 6 days to differentiate them to small intestinal cells that express the calcium transporter, CaT1. On day 3 after plating, old media is removed and replaced with fresh media (150 µl/well). On
20 day 6 the old media is removed and the cells are kept in treatment media (180 µl/well) that contained 10 % charcoal stripped fetal bovine serum (Hyclone, Logan, UT) in DMEM (low glucose, without phenol red; Invitrogen, Carlsbad, CA). The cells are treated with various concentrations of VDR ligands (from 0.01 nM to 10,000 nM concentration range) prepared in treatment media (20 µl/well). Twenty hours post-treatment, total RNA
25 is prepared by RNeasy 96 method as described by the manufacturer (Qiagen, Valencia, CA). The RNA is reverse transcribed and amplified for human CaT1 and GAPDH (control) messages by quantitative RT-PCR using ABI PRISM 7900HT Sequence Detection System according to manufacturer's instructions (Applied Biosystems, Foster City, CA). Optimized primer pairs and probes for human CaT1 and GAPDH genes are
30 obtained commercially (Applied Biosystems, Foster City, CA). Each 20 µl quantitative RT-PCR reaction in a 384-well Taqman PCR plate consists of forward and reverse


-67-

primers (900 nM), Taqman probe (200 nM), total RNA (4 µl form each well of the 96-well culture plate) and 10 µl of Taqman Universal PCR Master Mix (Roche Diagnostics, Indianapolis, IN). Reactions are incubated at 48°C for 30 minutes, followed by 10 minutes at 95°C and subjected to 40 cycles of PCR (95°C for 15 seconds followed by 60°C for 1 minute). GAPDH is used as an internal control and its primer and probe set are obtained commercially (Applied Biosystems, Foster City, CA).

WE CLAIM:

1. A compound represented by formula I or a pharmaceutically acceptable salt derivative thereof:

5



wherein;

R and R' are independently C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, or together R and R' form a substituted or unsubstituted, saturated or unsaturated carbocyclic ring having from 10 3 to 8 carbon atoms;



R_P, R'_P, and R_F are independently selected from the group consisting of hydrogen, halo, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ fluoroalkyl, -O-C₁-C₄ alkyl, -S-C₁-C₄ alkyl, -O-C₁-C₄ fluoroalkyl, -CN, -NO₂, acetyl, -S-C₁-C₄ fluoroalkyl, C₂-C₄ alkenyl, C₃-C₄ cycloalkyl, and C₃-C₄ cycloalkenyl;

15 (L₁), (L₂), (L₃), and (L_F) are divalent linking groups independently selected from the group consisting of

-69-


a bond,

oxygen



where each R40 is independently hydrogen, C₁-C₅ alkyl or C₁-C₅ fluoroalkyl;
where X1 is O, CH₂ or [H, OH];

5 Z_F is



where R4 and R5 are independently hydrogen, C₁-C₄ alkyl, -O-C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ haloalkyl, -NH(C₁-C₄ alkyl), or cyclopropyl, with the proviso that only one of R4 or R5 may be hydrogen;

10 Z_P is

methyl,

ethyl,

n-propyl,

1-methylethyl,

15 1-methylpropyl,

2-methylpropyl,

WO 2005/051936

-70-

- 1,1-dimethylethyl,
1,1-dimethylpropyl,
1,2-dimethylpropyl,
2,2-dimethylpropyl,
1-hydroxy-2,2-dimethylpropyl,
1-hydroxy-1,2,2-trimethylpropyl,
2-hydroxy-2-methylbutoxy
2-hydroxy-2-ethylbutoxy
2-hydroxy-2-ethyl-3-methylbutoxy
2-hydroxy-2-methyl-3-methylbutoxy
2-hydroxy-1,3,3-trimethylbutoxy
2-hydroxy-1-ethyl-3,3-dimethylbutoxy
2-hydroxy-1,2-diethylbutoxy
2-hydroxy-2-ethyl-1-methylbutoxy
3-methyl-3-hydroxypentyl,
3-methyl-3-hydroxypentenyl,
3-methyl-3-hydroxypentynyl,
3-ethyl-3-hydroxypentyl,
3-ethyl-3-hydroxypentenyl,
3-ethyl-3-hydroxypentynyl,
3-ethyl-3-hydroxy-4-methylpentyl,
3-ethyl-3-hydroxy-4-methylpentenyl,
3-ethyl-3-hydroxy-4-methylpentynyl,
3-propyl-3-hydroxypentyl,
3-propyl-3-hydroxypentenyl,
3-propyl-3-hydroxypentynyl,
1-hydroxy-2-methyl-1-(methylethyl)propyl
1-hydroxycyclopentenyl,
1-hydroxycyclohexenyl,
1-hydroxycycloheptenyl,
1-hydroxycyclooctenyl,
1-hydroxycyclopropyl,

-71-

1-hydroxycyclobutyl,
1-hydroxycyclopentyl,
1-hydroxycyclohexyl,
1-hydroxycycloheptyl, or
5 1-hydroxycyclooctyl.

2. The compound of claim 1 wherein









Z_P is 1,1-dimethylethyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-hydroxy-2,2-dimethylpropyl, or 1-hydroxy-1,2,2-trimethylpropyl, provided that (L₁), (L₂), (L₃) are all
10 bonds;

Z_F is selected from:

-C(O)NHMe,
-C(O)NHEt,
-C(O)NH(iPr),
15 -C(O)NH(tBu),
-C(O)NH(CF₃),
-C(O)N(Me)₂,
-C(O)NMeEt,
-C(O)NMe(iPr),
20 -C(O)NMe(tBu),
-C(O)NMe(CF₃),
-C(O)N(Me)F,
-C(O)N(Et)F
-C(O)N(iPr)F,
25 -C(O)N(tBu)F,
-C(O)N(Et)₂, or
-C(O)NET(iPr); and

Z_F is

-72-



or

-73-

or a pharmaceutically acceptable salt or prodrug thereof.

3. The compound of claim 2 wherein


Z_F is selected from:

- 5 -C(O)NHMe,
-C(O)NHEt,
-C(O)NH(iPr),
-C(O)NH(tBu),
-C(O)N(Me)₂,
10 -C(O)NMeEt,
-C(O)NMe(iPr),
-C(O)NMe(tBu),
-C(O)N(Et)₂, or
-C(O)NEt(iPr);

15 or a pharmaceutically acceptable salt or prodrug thereof.


4. A compound or a pharmaceutically acceptable salt or ester prodrug derivative thereof represented by formulae A to J as follows:

A)




20

B)




C)

-74-




E)




5


F)



G)




H)



10


-75-

I)



, and


J)



, and

5

K)



5. The salt derivative of the compound according to any of claims 1 to 4 wherein
the salt is sodium or potassium.

10

6. A pharmaceutical formulation comprising the compound of any one of claims
1 to 4 together with a pharmaceutically acceptable carrier or diluent.

15

7. A formulation for treating osteoporosis comprising:

Ingredient (A1): a vitamin D receptor modulator of claim 1 to 4;

Ingredient (B1):

one or more co-agents selected from the group consisting of:

a. estrogens,

b. androgens,

-76-

- c. calcium supplements,
- d. vitamin D metabolites,
- e. thiazide diuretics,
- f. calcitonin,
- 5 g. bisphosphonates,
- h. SERMS, and
- i. fluorides; and

Ingredient (C1): optionally, a carrier or diluent.

10 8. The formulation of claim 7 wherein the weight ratio of (A1) to (B1) is
from 10:1 to 1:1000.

9. A formulation for treating psoriasis comprising:

15 Ingredient (A2): a vitamin D receptor modulator according to any
one of claims 1 to 4;

Ingredient (B2):

one or more co-agents that are conventional for treatment psoriasis
selected from the group consisting of:

- a. topical glucocorticoids ,
- b. salicylic acid,
- 20 c. crude coal tar; and

Ingredient (C2): optionally, a carrier or diluent.

10 10. The formulation of claim 9 wherein the weight ratio of (A2) to (B2) is
25 from 1:10 to 1:100000.

11. A method of treating a mammal to prevent or alleviate the pathological
effects of Acne, Actinic keratoses, Alopecia , Alzheimer's disease, Bone maintenance in
zero gravity, Bone fracture healing, Breast cancer, Chemoprevention of Cancer, Crohn's
30 disease, Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia , Type II
diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum
secretion, Osteomalacia, Osteoporosis, Insufficient dermal firmness, Insufficient dermal

-77-

hydration, Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid arthritis, Scleroderma, Skin cancer, Systemic lupus erythematosus, Skin cell protection from Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles; wherein the method comprises administering a pharmaceutically effective amount of at least one compound of claim 1 or 2 or 3.

12. The method of claim 11 for the treatment of psoriasis.
13. The method of claim 11 for the treatment of osteoporosis.
- 10 14. A method of claim 11 for treating a mammal to prevent or alleviate skin cell damage from Mustard vesicants.
- 15 15. A method of treating a mammal to prevent or alleviate the pathological effects of Benign prostatic hyperplasia or bladder cancer wherein the method comprises administering a pharmaceutically effective amount of at least one compound according to any one of claims 1 to 4.
- 20 16. A method of treating or preventing disease states mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of a compound of Claim 1 to 4.
- 25 17. A compound as claimed in any one of Claims 1 to 4 for use in treating a mammal to prevent or alleviate the pathological effects of Acne, Actinic keratosis, Alopecia , Alzheimer's disease, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer, Chemoprevention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia , Type II diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum secretion, Osteomalacia, Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration, 30 Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid arthritis, Scleroderma, Skin cancer, Systemic lupus erythematosus, Skin cell damage from Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles.

18. A compound as claimed in any one of Claims 1 to 4 for use in treating a mammal to prevent or alleviate the pathological effects of benign prostatic hyperplasia or bladder cancer.

5

19. A compound as claimed in any one of Claims 1 to 4 for use in treating or preventing disease states mediated by the Vitamin D receptor.

20. A compound as claimed in Claim 1 substantially as hereinbefore described
10 with reference to any of the Examples.

21. A process for preparing a compound as claimed in claim 1 substantially as hereinbefore described with reference to any of the Examples.

15 22. The use of a compound as claimed in claim 1 substantially as herein described with reference to any of the Assays and Tables for mediating the Vitamin D receptor.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/035527

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D307/68 A61K31/341 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	WO 00/10958 A (LIGAND PHARMACEUTICALS INCORPORATED) 2 March 2000 (2000-03-02) page 1, line 4 – line 14; claim 1 -----	1-22
P, Y	WO 03/101978 A (ELI LILLY AND COMPANY; DAHNKE, KARL, ROBERT; GAJEWSKI, ROBERT, PETER;) 11 December 2003 (2003-12-11) claims 1,18 -----	1-22



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

30 March 2005

07/04/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax. (+31-70) 340-3016

Authorized officer

Seelmann, I

INTERNATIONAL SEARCH REPORT

International Application No PCT/US2004/035527

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0010958	A	02-03-2000	US AT AU AU CA DE DE DK EP ES JP PT WO	6218430 B1 253032 T 756336 B2 5485299 A 2339775 A1 69912450 D1 69912450 T2 1107940 T3 1107940 A1 2207273 T3 2002523388 T 1107940 T 0010958 A1	17-04-2001 15-11-2003 09-01-2003 14-03-2000 02-03-2000 04-12-2003 29-07-2004 08-03-2004 20-06-2001 16-05-2004 30-07-2002 31-03-2004 02-03-2000
WO 03101978	A	11-12-2003	AU BR CA EP WO	2003233505 A1 0309983 A 2485503 A1 1511740 A1 03101978 A1	19-12-2003 22-02-2005 11-12-2003 09-03-2005 11-12-2003